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Abstract
Statins reduce the risk of major coronary outcomes and all cause mortality. They are generally well tolerated,
but are associated with uncommon but serious adverse events. Pharmacokinetic studies show statins
metabolized by the CYP3A4 isoenzyme (statin 3A4 substrates) are susceptible to drug interactions when
concomitantly administered with drugs that inhibit the CYP3A4 isoenzyme (CYP3A4 inhibitors) -
potentially increasing the risk for adverse events. Studies to evaluate the clinical importance of the statin-
CYP3A4 inhibitor interaction are limited to anecdotal findings. This research endeavored to evaluate the
clinical importance of the statin-CYP3A4 inhibitor drug interaction in two empiric investigations and a
methodologic study.
The preliminary empiric study was an analysis of spontaneous rhabdomyolysis reports. It showed an increased
rhabdomyolysis reporting rate for simvastatin (a statin 3A4 substrate) but not for pravastatin (a statin
non-3A4 substrate) with a concomitant CYP3A4 inhibitor. Substantial internal validity limitations, inherent
in spontaneous reporting analyses, warranted additional research.
To further assess the clinical importance of this drug interaction, we evaluated the validity of the multinomial
propensity score as a confounding adjustment method in a simulated drug interaction study. The results from
the simulation study provided support for using the multinomial propensity score in the second empiric
study. The results showed the multinomial propensity score reduced bias, had greater coverage probability,
and increased precision compared to binary propensity score methods. Investigators studying multinomial
exposures, such as drug interactions, should consider the multinomial propensity score for confounding
adjustment.
The second empiric study was a large retrospective cohort study. The objective was to evaluate the hazard of
muscle toxicity, renal dysfunction, and hepatic dysfunction among patients exposed to statin 3A4 substrates
(atorvastatin and simvastatin) compared to statin non-3A4 substrates (fluvastatin, pravastatin, and
rosuvastatin) with and without CYP3A4 inhibitor concomitancy. We found no overall increased hazard of
muscle toxicity, renal dysfunction, or hepatic dysfunction associated with statin 3A4 substrates compared to
statin non-3A4 substrates with versus without a concomitant CYP3A4 inhibitor. Given the magnitude and
validity of this investigation, the drug interaction between statins and CYP3A4 inhibitors therefore does not
represent a substantial public health concern.
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ABSTRACT 
 
CLINICAL IMPORTANCE OF THE DRUG INTERACTION BETWEEN STATINS AND CYP3A4 
INHIBITORS 
 
Christopher G. Rowan 
 
Supervisor: Brian L. Strom MD, MPH 
 
Statins reduce the risk of major coronary outcomes and all cause mortality. They are 
generally well tolerated, but are associated with uncommon but serious adverse events. 
Pharmacokinetic studies show statins metabolized by the CYP3A4 isoenzyme (statin 3A4 
substrates) are susceptible to drug interactions when concomitantly administered with drugs that 
inhibit the CYP3A4 isoenzyme (CYP3A4 inhibitors) - potentially increasing the risk for adverse 
events.  Studies to evaluate the clinical importance of the statin-CYP3A4 inhibitor interaction are 
limited to anecdotal findings.  This research endeavored to evaluate the clinical importance of the 
statin-CYP3A4 inhibitor drug interaction in two empiric investigations and a methodologic study.   
The preliminary empiric study was an analysis of spontaneous rhabdomyolysis reports.  It 
showed an increased rhabdomyolysis reporting rate for simvastatin (a statin 3A4 substrate) but 
not for pravastatin (a statin non-3A4 substrate) with a concomitant CYP3A4 inhibitor.  Substantial 
internal validity limitations, inherent in spontaneous reporting analyses, warranted additional 
research.  
To further assess the clinical importance of this drug interaction, we evaluated the validity of 
the multinomial propensity score as a confounding adjustment method in a simulated drug 
interaction study. The results from the simulation study provided support for using the multinomial 
propensity score in the second empiric study. The results showed the multinomial propensity 
score reduced bias, had greater coverage probability, and increased precision compared to 
binary propensity score methods. Investigators studying multinomial exposures, such as drug 
interactions, should consider the multinomial propensity score for confounding adjustment. 
The second empiric study was a large retrospective cohort study. The objective was to 
evaluate the hazard of muscle toxicity, renal dysfunction, and hepatic dysfunction among patients 
exposed to statin 3A4 substrates (atorvastatin and simvastatin) compared to statin non-3A4 
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substrates (fluvastatin, pravastatin, and rosuvastatin) with and without CYP3A4 inhibitor 
concomitancy.  We found no overall increased hazard of muscle toxicity, renal dysfunction, or 
hepatic dysfunction associated with statin 3A4 substrates compared to statin non-3A4 substrates 
with versus without a concomitant CYP3A4 inhibitor. Given the magnitude and validity of this 
investigation, the drug interaction between statins and CYP3A4 inhibitors therefore does not 
represent a substantial public health concern.    
 
 
 
iii
TABLE OF CONTENTS 
ABSTRACT ...................................................................................................................................... ii 
Table of Contents............................................................................................................................ iv 
List of Tables and figures................................................................................................................. v 
Dissertation Introduction ..................................................................................................................1 
Project 1: Clinical importance of the drug interaction between statins and CYP3A4 inhibitors 
- analysis of spontaneous reports of rhabdomyolysis (AERS).................................................4 
Abstract..............................................................................................................................5 
Introduction........................................................................................................................6 
Methods .............................................................................................................................8 
Results.............................................................................................................................11 
Discussion .......................................................................................................................14 
Tables ..............................................................................................................................17 
Project 2: A comparison of multinomial and binary propensity score methods in a simulated 
drug-drug interaction study ....................................................................................................24 
Abstract............................................................................................................................25 
Introduction......................................................................................................................27 
Methods ...........................................................................................................................28 
Results.............................................................................................................................37 
Discussion .......................................................................................................................40 
Tables ..............................................................................................................................43 
Project 3: Clinical importance of the drug interaction between statins and CYP3A4 inhibitors 
- A Retrospective Cohort Study in The Health Improvement Network (THIN).......................53 
Abstract............................................................................................................................55 
Introduction......................................................................................................................56 
Methods ...........................................................................................................................58 
Results.............................................................................................................................63 
Discussion .......................................................................................................................65 
Tables ..............................................................................................................................69 
Dissertation Conclusion .................................................................................................................77 
References.....................................................................................................................................78 
 
 
iv
 
 
v
 
LIST OF TABLES AND FIGURES 
Project 1: Clinical importance of the drug interaction between statins and CYP3A4 inhibitors - 
analysis of spontaneous reports of rhabdomyolysis (AERS)...........................................................4 
AERS Table 1 ............................................................................................................................17 
AERS Table 2 ............................................................................................................................18 
AERS Table 3 ............................................................................................................................19 
AERS Table 5a ..........................................................................................................................21 
AERS Table 5b ..........................................................................................................................21 
AERS Table 6a ..........................................................................................................................22 
AERS Table 6b ..........................................................................................................................22 
AERS Table 7 ............................................................................................................................23 
Project 2: A comparison of multinomial and binary propensity score methods in a simulated drug-
drug interaction study.....................................................................................................................24 
Methods Figure 1 percent bias (spectrum of confounding) .......................................................43 
Methods Figure 1a coverage probability (spectrum of confounding).........................................43 
Methods Table 1 coverage probability and MSE (spectrum of confounding) ............................43 
Methods Figure 2: percent bias (Sample size) ..........................................................................44 
Methods Table 2: coverage probability and MSE (sample size)................................................44 
Methods Figure 3: percent bias (proportion A2=1) ....................................................................45 
Methods Table 3: coverage probability and MSE (Proportion A2=1) ........................................45 
Methods Figure 4: percent bias (assoc. between the object and precipitant drugs) .................46 
Methods Table 4: coverage probability and MSE (assoc. between the object and precipitant 
drugs) .........................................................................................................................................46 
Methods Figure 5: percent bias (strength of A1*X1 interaction) ................................................47 
Methods Table 5: coverage probability and MSE (strength of A1*X1 interaction).....................47 
Methods Figure 6: percent bias (Frequency of outcome occurrence (Y=1)) .............................48 
Methods Table 6: coverage probability and MSE (Frequency of outcome occurrence (Y=1))..48 
Methods Figure 7: percent bias (Strength of the interaction ratio (I*R)) ....................................49 
Methods Table 7: coverage probability and MSE (Strength of the interaction ratio (I*R)).........49 
Methods Figure 8: percent bias (covariate form) .......................................................................50 
Methods Table 8: coverage probability and MSE (covariAte form) ...........................................50 
Methods Figure 9 (PS1 balance diagnostic) ..............................................................................51 
Methods Figure 10 (PS2 balance diagnostic) ............................................................................51 
Methods Figure 11 (PS3 balance diagnostic) ............................................................................51 
Methods Figure 12a (PS4a balance diagnostic) ........................................................................52 
Methods Figure 12b (PS4b balance diagnostic) ........................................................................52 
Methods Figure 12c (PS4c balance diagnostic) ........................................................................52 
Methods Figure 12d (PS4d balance diagnostic) ........................................................................52 
Project 3: Clinical importance of the drug interaction between statins and CYP3A4 inhibitors - A 
Retrospective Cohort Study in The Health Improvement Network (THIN) ....................................53 
THIN Figure 1.............................................................................................................................69 
THIN Table 1..............................................................................................................................70 
THIN Table 2a............................................................................................................................71 
THIN Table 2b............................................................................................................................72 
THIN Table 2c ............................................................................................................................73 
THIN Table 3..............................................................................................................................74 
THIN Table 4..............................................................................................................................75 
THIN Table 5..............................................................................................................................76 
DISSERTATION INTRODUCTION 
 
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are 
extremely effective in the treatment of dyslipidemia. They have been shown to reduce the risk of 
major coronary outcomes and all cause mortality.1, 2 While statins are well tolerated by the vast 
majority of patients, they are associated with infrequent muscle, renal, and hepatic adverse 
events.3-9  Statin associated muscle and renal toxicity occur on a continuum from minor myalgias 
and proteinuria to severe myositis, renal failure, and fatal rhabdomyolysis.10-12  Statin associated 
hepatic toxicity is characterized by transaminitis and rarely serious hepatic dysfunction or hepatic 
failure.13, 14  Clinical trials, case reports, and observational studies show these adverse events are 
associated with all marketed statins.9, 15-17 While the incidence of serious statin adverse events is 
low, muscle toxicity is a leading cause of statin discontinuation - particularly among patients 
treated with high-potency statin therapy.18, 19  It has been shown that statin-related adverse 
events occur in a dose dependent manner.  It has been hypothesized that they may be 
exacerbated by pharmacokinetic (PK) statin-drug interactions that increase statin system 
exposure.8, 15, 20 17, 21 22-25   
However, not all statins have the same drug interaction potential.   The unique 
physiochemical property of each statin makes certain statins more likely to interact with 
concomitant medications. Of particular importance is the drug interaction between statins and 
drugs that inhibit the CYP3A4 metabolic pathway.  The CYP3A4 isoenzyme is the most prevalent 
isoenzyme in the cytochrome P450 enzyme system.  The CYP3A4 isoenzyme metabolizes more 
than 50% of all marketed pharmaceuticals.26 Statins that undergo phase I metabolism by the 
CYP3A4 isoenzyme are referred to as statin 3A4 substrates.  Statins that do no use the CYP3A4 
isoenzyme metabolic pathway are referred to as statin non-3A4 substrates. This investigation 
focuses on statin phase I metabolic inhibition, specifically the clinical importance of the drug 
interaction between statins and concomitant drugs which inhibit the CYP3A4 isoenzyme 
(CYP3A4 inhibitors). CYP3A4 inhibitors prevent CYP3A4 isoenzymes from metabolizing other 
drugs (e.g., statin 3A4 substrates). As serious statin adverse events are potency and plasma 
concentration related, it is recognized that plasma levels of statins 3A4 substrates may increase 
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with concomitant administered of CYP3A4 inhibitors.27  Currently marketed pharmaceuticals that 
are CYP3A4 inhibitors are commonly used.  They include calcium channel blockers, H2 receptor 
antagonists, antibiotics, antifungals, antidepressants, antiretrovirals, and immunosuppresants.28  
The purpose of this investigation is to study the clinical importance of the drug interaction 
between statins and CYP3A4 inhibitors.  Given the physiochemical properties, drug interaction 
potential, and prior research, we hypothesized an increased relative hazard for statin 3A4 
substrates compared to statin non-3A4 substrates with CYP3A4 inhibitor concomitancy. Studies 
to quantify the hazard of statin-related adverse events for different statins (with different 
metabolism) with CYP3A4 inhibitor concomitancy have not been conducted.   
We conducted two empiric investigations and a methodologic study to evaluate the clinical 
importance of the drug interaction between statins and CYP3A4 inhibitors. The first empiric study 
uses spontaneous reports of rhabdomyolysis associated with simvastatin and pravastatin to 
determine if the CYP3A4 mediated drug interaction results in a selective increase in 
rhabdomyolysis reporting rates based on different statin metabolic pathways. Given the 
aforementioned physiochemical characteristics of each statin, we hypothesize an increased risk 
for simvastatin, but not for pravastatin, with CYP3A4 inhibitor concomitancy. The project title is: 
Clinical importance of the drug interaction between statins and CYP3A inhibitors - analysis of 
spontaneous reports of rhabdomyolysis. Its specific aim is: to determine if the CYP3A4 mediated 
drug interaction results in a selective increase in spontaneous rhabdomyolysis reporting rates 
based on different statin metabolic pathways. The study’s hypothesis is: because of the potential 
increased statin exposure when a statin 3A4 substrate is concomitantly prescribed with a 3A4 
inhibitor, there will be greater spontaneous rhabdomyolysis reporting compared to patients 
concomitantly prescribed a statin non-3A4 substrate and a 3A4 inhibitor. 
The methodologic study is a simulation study to evaluate propensity score methods in the 
setting of a drug-drug interaction study.  In drug-drug interaction studies, such as with 
aforementioned empiric studies of statins and CYP3A4 inhibitors, there may be more than two 
non-ordered exposure categories. No applied methodologic research using simulations to 
evaluate different propensity score methods in multiple, non-ordered exposure categories have 
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been published.  This study evaluated relative bias and coverage probability associated with 
different binary and multinomial propensity score methods. Researchers studying drug 
interactions may find this research informative to guide their confounding adjustment method. By 
evaluating each propensity score method under different scenarios, we intended to provide drug-
drug interaction researchers with a broadly applicable tool that will guide their choice of PS 
method.  Specifically, the title is:  A comparison of multinomial and binary propensity score 
methods in a drug-drug interaction study. Its specific aim is to use Monte Carlo simulation to 
compare bias, precision, and coverage probability of multinomial and multiple binary propensity 
score methods in the setting of drug-drug interaction studies. The study’s hypothesis is: the 
multinomial propensity score will reduce bias, increase precision, and have better empiric 
coverage than multiple different binary propensity score methods. 
The second empiric study endeavors to evaluate the clinical importance of the drug 
interaction between statins and CYP3A4 inhibitors in a large retrospective cohort study using a 
validated electronic medical record database.  In three separate cohort studies, we evaluated the 
relative hazard of (i) muscle toxicity, (ii) kidney dysfunction, and (iii) hepatic dysfunction 
associated with statin 3A4 substrates compared to statin non-3A4 substrates with CYP3A4 
inhibitor concomitancy. The project title is: Clinical importance of the drug interaction between 
statins and CYP3A4 inhibitors - THIN Cohort study. Its specific aim is: to compare the relative 
hazard of muscle toxicity, kidney dysfunction, and hepatic dysfunction following concomitant 
therapy with a: [statin CYP3A4 substrate plus a CYP3A4 inhibitor] vs. [statin non-CYP3A4 
substrate plus a CYP3A4 inhibitor]. The study’s hypothesis is: because of the potential increased 
statin exposure when a statin CYP3A4 substrate is concomitantly prescribed with a CYP3A4 
inhibitor, there will be greater relative hazard of muscle toxicity, renal dysfunction, and hepatic 
dysfunction compared to patients concomitantly prescribed a statin non-CYP3A4 substrate and a 
CYP3A4 inhibitor. 
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PROJECT 1: CLINICAL IMPORTANCE OF THE DRUG INTERACTION BETWEEN STATINS 
AND CYP3A4 INHIBITORS - ANALYSIS OF SPONTANEOUS REPORTS OF 
RHABDOMYOLYSIS (AERS) 
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Five key points: 
1. We studied spontaneous reports of rhabdomyolysis associated simvastatin, a CYP3A4 
substrate, and pravastatin, a non-CYP3A4 substrate, for evidence of CYP3A4 interaction. 
2. We found 3 out of 25 pravastatin reports and 56 out of 118 simvastatin reports were associated 
with a concomitant CYP3A4 inhibitor 
3. Fifteen percent of pravastatin and 12.5 percent of simvastatin prescriptions were concomitantly 
prescribed with a CYP3A inhibitor. 
4. The adverse event reporting rate ratios for rhabdomyolysis (statin w/CYP3A4 inhibitor vs. statin 
w/o CYP3A4 inhibitor) were 0.77 and 6.34 for pravastatin and simvastatin respectively. 
5. The comparison of reporting rate ratios (simvastatin/pravastatin) suggests effect modification 
by CYP3A4 inhibitor as predicted in FDA approved labeling for simvastatin. 
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ABSTRACT 
Purpose:  To assess spontaneous reports of rhabdomyolysis associated with simvastatin and 
pravastatin for evidence of concomitant CYP3A4 inhibitor interaction. Clinical trial results 
advocate for the use of cholesterol lowering in high-risk patients including diabetics and the 
elderly.  Given the association between advancing age, metabolic, and cardiovascular disease, 
many patients are treated with concomitant medications upon statin initiation. Although statins are 
generally safe, minor and severe adverse reactions arise, especially when given to patients 
taking concomitant medications that inhibit the statin clearance and lead to increased statin 
plasma concentration.   
Methods: We conducted a comparative case series of rhabdomyolysis reports associated with 
simvastatin and pravastatin. Domestic spontaneous reports were obtained from the FDA's 
Adverse Event Reporting System (AERS). Drug utilization data were obtained from IMS HEALTH 
and the National Ambulatory Medical Care Survey (NAMCS). Adverse event reporting rates 
(AER) and ratios (AERR) of rhabdomyolysis associated with simvastatin and pravastatin - 
stratified the presence and absence of a concomitant CYP3A4 inhibitor concomitancy were 
determined. 
Results: Stratification by CYP3A4 inhibitor concomitancy did not change the rhabdomyolysis AER 
for pravastatin with versus without a CYP3A4 inhibitor (2.4 cases and 3.1 cases per 10 million Rx, 
respectively). However, stratification of simvastatin reports with versus without a concomitant 
CYP3A4 inhibitor resulted in a rhabdomyolysis AER of 38.4 and 6.0 cases per 10 million Rx. The 
corresponding AERR with versus without a CYP3A4 inhibitor was 0.77 for pravastatin and 6.43 
for simvastatin. 
Conclusions:  
Spontaneous adverse event reports provide evidence of increased risk for rhabdomyolysis based 
on the interaction between simvastatin and selected CYP3A4 inhibitors.  
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INTRODUCTION 
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are 
extremely effective in the treatment of dyslipidemias.29, 30 They are well tolerated by the vast 
majority of patients, but are infrequently associated with muscle related toxicity.  Statin associated 
muscle toxicity occurs on a continuum from minor myalgias to potentially fatal rhabdomyolysis.10  
Though rare, rhabdomyolysis has been reportedly associated with all currently marketed statins. 
Postmarketing reports of rhabdomyolysis resulted in the suspension of cerivastatin marketing, 
likely due to a drug-drug interaction.23  However, because statins have variable physiochemical 
properties, certain statins may be more or less likely to interact with concomitant medications. 
Due to high affinity and selectivity for the HMG-CoA reductase enzyme, statins have little 
potential to alter the pharmacokinetics of other drugs.31  However, the unique pharmacokinetic 
(PK) characteristics of each statin may substantially impact their susceptibility to be modified by 
concomitant medications.27  The PK differences between statins include: solubility, phase I and II 
metabolism, utilization of hepatic transporters, formation of active metabolites, bioavailability, 
protein binding, and excretion. Importantly, simvastatin (SV) and lovastatin (LV) are administered 
as lactone pro-drugs while the other statins are administered as β-hydroxy acids.  SV and LV 
lactone undergo hydrolysis in the plasma, intestinal mucosa, and liver to form active β-hydroxy 
acids.32-36 One PK characteristic shared by all statins is extensive first pass hepatic extraction.   
Hepatic extraction occurs by two primary mechanisms - active transport and passive 
diffusion.  Organic anion transporting polypeptide (OATP) is the primary membrane protein which 
actively transports hydrophilic statins pravastatin (PV) and rosuvastatin (RV) from portal 
circulation into the hepatocyte (influx).  The lipophilic statins atorvastatin (AV), CV, fluvastatin 
(FV), LV, and SV enter mainly by passive diffusion; however, the acid forms of these statins also 
utilize active transport mechanisms.27, 37-40  
Following entry into the hepatocyte each statin undergoes a unique cascade of metabolic 
and non-metabolic processes which ultimately results in cholesterol biosynthesis inhibition and 
statin elimination.  The metabolic processes include phase I oxidation (mediated by cytochrome 
P450 (CYP) isoenzymes) and phase II glucuronidation (mediated by UDP glucuronosyl 
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transferase (UGT)). The CYP isoenzymes responsible for phase I statin metabolism are 3A4, 
2C8, 2C9, and 2C19. Atorvastatin, LV, and SV are oxidized by the CYP3A4 isoenzyme to form 
both active and inactive metabolites.41, 42 Cerivastatin (CV) is oxidized by CYP2C8 and to a lesser 
extent CYP3A4.43 Fluvastatin (FV) is oxidized by CYP2C9.39, 43  Pravastatin (PV) has no phase I 
metabolism and is minimally metabolized by phase II glucuronidation. Rosuvastatin (RV) also has 
negligible phase I metabolism (by  CYP2C9 and CYP2C19) and is primarily eliminated as the 
unchanged parent compound.36, 44  
Following hepatocyte entry and metabolism (phase I and II), statins exert their cholesterol 
inhibitory effect and are subsequently eliminated. However, a varying proportion of statin reaches 
systemic circulation, by efflux transport and passive diffusion.27, 37, 38 The efflux transport proteins: 
P-glycoprotein (P-gp) and multidrug resistance associated protein 2 (MRP2), are believed to 
affect the disposition, bioavailability and elimination of all statins - primarily in the acid form.45 For 
most statins, elimination occurs through biliary excretion, PV is partially eliminated by renal 
excretion.  Inhibition of statin metabolism (phase I or II) and/or active membrane transporters 
(influx or efflux) may result in elevated plasma concentrations and has the potential to increase 
the risk for statin-related adverse events.  
Gemfibrozil (GEM) and cyclosporine (CSA) have been shown to interact with statins via both 
metabolic and hepatic transport pathways.  Shitara et al showed the drug interaction between 
GEM and CV occurred via GEM inhibiting CV hepatic uptake (via OATP) and oxidation (via 
CYP2C8).46  Similarly, CSA has been shown to inhibit hepatic uptake (OATP), efflux transporters 
(P-gp and MRP2), and oxidation (via CYP3A4).47 Olbricht et al showed a 5 and 20 fold increase 
in area under the curve (AUC) for PV and LV respectively in kidney transplant patients treated 
with CSA.48 Given PV is not a CYP3A4 substrate, the increased AUC is the likely result of 
transporter mediated inhibition.  
This investigation focuses on statin phase I metabolic inhibition, specifically the drug 
interaction between statins and concomitant drugs which inhibit CYP3A4 mediated metabolism 
(CYP3A4 inhibitors).  As serious statin adverse events are dose and plasma concentration 
related, it is recognized that plasma levels of statins oxidized by the CYP3A4 isoenzyme may 
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increase when these statins are concomitantly administered with CYP3A4 inhibitors.41, 49, 50 Many 
commonly used pharmaceuticals are CYP3A4 inhibitors.28  Some of the drug classes that include 
CYP3A4 inhibitors are calcium channel blockers, antibiotics, antifungals, antidepressants, 
anitretrovirals, and immunosuppresants.28 
The CYP3A4 isoenzyme metabolizes more than 50% of marketed drugs.26  A recent 
investigation showed 25% of new statin initiators received a concomitant CYP3A4 inhibitor in the 
first year of statin therapy.51 Case reports, risk-factor models, and clinical trials have shown 
concomitant administration of statins and CYP3A4 inhibitors may increase the risk for 
rhabdomyolysis.52-54 Because of the potential increased risk, some statin product labels warn 
against concomitant administration with CYP3A4 inhibitors. 
To study the clinical impact of this association we studied two statins with different Phase I 
metabolism, but similar hepatic transport mechanisms.  SV (a CYP3A4 substrate) was chosen as 
the object drug and PV (a non-CYP3A4 substrate) as the comparator object drug.  While the 
phase I metabolic pathways for SV and PV are different, both statins should be similarly impacted 
by influx and efflux hepatic transporters (via OATP, P-gp, and MRP2).55, 56  Based on published 
reports by Hsiang37 and Chen45 et al, it is believed that hepatic transport (influx and efflux) of SV 
acid and PV are equally involved.   Any transporter inhibition, due to co-administration of a 
CYP3A4 inhibitor (e.g., CSA), should impact transporter mediated shunting of SV acid and PV 
similarly.  
Studies to quantify the hazard of rhabdomyolysis for different statins (with different 
metabolism) with CYP3A4 inhibitor concomitancy have not been conducted.  The purpose of this 
investigation is to study spontaneous reports of rhabdomyolysis associated with SV and PV to 
determine if the CYP3A4 mediated drug interaction results in a selective increase in 
rhabdomyolysis reporting rates based on different statin metabolic pathways. Given the 
aforementioned physiochemical characteristics of each statin, we hypothesize an increased risk 
for SV, but not for PV, with CYP3A4 inhibitor concomitancy. 
METHODS 
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We conducted a comparative case series of spontaneous reports of rhabdomyolysis 
associated with PV and SV to assess interaction with selected CYP3A4 inhibitors. To control for 
population exposure to each statin, we used the estimated total number of PV and SV 
prescriptions as denominators for each case group. 
Case source: This analysis was conducted at the Food and Drug Administration’s (FDA) 
Center for Drug Evaluation and Research (CDER).  Cases consisted of domestic (U.S.) 
spontaneous adverse event reports of rhabdomyolysis associated with PV and SV.  These 
reports were submitted to the FDA by pharmaceutical manufacturers or health care professionals 
through the MedWatch program.  MedWatch reports are archived in CDER’s Adverse Events 
Reporting System (AERS) database and coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA). A concise review of the history and treatment of adverse drug 
event reports at CDER, including epidemiological inference, has been reported seaparately.57  
Case definition:  
Spontaneous reports of rhabdomyolysis associated with PV and SV were obtained from the 
AERS database.  We acquired all cases of rhabdomyolysis associated with these two agents 
from market launch (November 1991 for PV; January 1992 for SV) through July 2001.   The cut-
off date of July 2001 was selected to limit the effect of stimulated rhabdomyolysis reporting 
following the suspension of cerivastatin marketing in August 2001.  Reports were selected using 
the MedDRA terms rhabdomyolysis, myopathy, or myalgia with further restriction for 
rhabdomyolysis that required hospitalization. After identification of putative cases, all reports were 
manually reviewed by the authors (C.R., A.B.).   
A case of rhabdomyolysis was defined as a patient with a health care professional (HCP) 
diagnosis of rhabdomyolysis or a HCP diagnosis of myositis or myopathy with a creatine 
phosphokinase (CPK) > 10,000 IU/L.  Exclusion criteria included non-U.S. reports, non-HCP 
reports, duplicate reports, “hearsay” reports, published reports, and cases with a history of: non-
statin-related rhabdomyolysis, myositis, dermatomyositis, renal transplantation, or HIV infection / 
treatment. In order to reduce confounding by concomitant statin-fibrate exposure, reports listing 
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concurrent use of gemfibrozil (GEM) were excluded from the primary analysis, but were included 
in a secondary analysis. 
Case exposure definition:  
Each report was carefully reviewed for specific mention of recent administration of PV or SV 
and a concomitant CYP3A4 inhibitor. We further verified the temporality of the statin without a 
CYP3A4 inhibitor or the statin-CYP3A4 inhibitor concomitancy to the event date.  We required 
both the statin and the CYP3A4 inhibitor to be listed (within 30 days of each other) in either the 
concomitant medications section or specific mention of a concomitant (statin-CYP3A4 inhibitor) 
therapy in the report narrative.  Additionally, we required documentation of the statin-CYP3A4 
inhibitor concomitancy to be no more than 30 days prior to the event date or specific mention of 
close temporal association between concomitant exposure and the event in the narrative.  
The CYP3A4 inhibitors chosen for this investigation were: cyclosporine, clarithromycin, 
erythromycin, diltiazem, verapamil, mibefradil, itraconazole, ketoconazole, fluconazole, 
nefazodone, and fluvoxamine. Despite our attempt to study CYP3A4 inhibitors known for potent 
and selective CYP3A4 inhibition, some of the selected CYP3A4 inhibitors also inhibit other 
metabolic and uptake transport pathways.  
Population exposure source:  
Drug utilization data were acquired for the purpose of estimating total U.S. exposure to PV 
and SV with and without a CYP3A4 inhibitor during the study period (denominator data).  These 
data were acquired from two different sources - IMS HEALTH National Prescription Audit Plus 
(NPA Plus) and the NAMCS. NPA Plus data were used to estimate the total number PV and SV 
prescriptions dispensed in the United States from November 1991 through July 2001.15 The 
concomitant statin-CYP3A4 inhibitor frequency was determined using the National Ambulatory 
Medical Care Survey (NAMCS).  
NAMCS is a national probability sample survey of office-based physicians conducted by the 
National Center for Health Statistics, Centers for Disease Control and Prevention.  Statistics 
derived from NAMCS are representative of all ambulatory care visits to physicians engaged in 
non-federal, office-based health care. Participating physicians agree to systematic sampling and 
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review (via chart abstraction) of patient visits during a randomly selected week of the year.  For 
the sampled visits, the physician provides details of specific patient information including patient 
demographics, reason for the visit, up to three medical diagnoses, treatments, and disposition. 
New and continued prescriptions are recorded as well as other treatments and recommendations. 
Data gathered from this survey are transcribed into standard international classification of 
diseases (ICD-9) nomenclature.  Concomitancy data for PV and SV with a CYP3A4 inhibitor were 
collected from NAMCS during the time period 1993-2001. NAMCS is a practical source to 
estimate statin-CYP3A4 concomitancy, although it may not be representative of the overall United 
States concomitant frequency distribution.  
In order to calculate the number of statin prescriptions with a concomitant CYP3A4 inhibitor, 
we multiplied the total number of PV and SV prescriptions by the concomitant frequency 
proportion for PV and SV with a CYP3A4 inhibitor. The remainder of each calculation is the total 
number of PV and SV prescriptions without a CYP3A4 inhibitor. 
Measures of effect:  
The adverse event reporting rate (AER), measured as number of cases per 10 million 
prescriptions, will be calculated using the actual number of cases of rhabdomyolysis associated 
with either PV or SV (as the numerator) and the estimated population exposure as the 
denominator. The adverse event reporting rate ratio (AERR) will also be calculated to reveal the 
relative effect for each statin with and without a concomitant CYP3A4 inhibitor.  
The primary analysis consisted of calculating the rhabdomyolysis AER and AERR 
associated with PV and SV stratified by the presence or absence of a CYP3A4 inhibitor. 
Secondary analyses were conducted to evaluate the potential impact of statin dose and to 
compare the rhabdomyolysis AER and AERR with statin-GEM concomitancy. 
RESULTS 
A search of the AERS database MedWatch reports from 1991 through July 2001, recovered 
73 and 321 potential cases of rhabdomyolysis associated with PV and SV respectively.  Following 
hands-on review, 25 and118 reports, for PV and SV respectively, were classified as unique cases 
fitting the case definition. Demographic and clinical characteristics of these cases are shown in 
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Table 1.  The median age for both groups was 66 years.  Fifty-five percent and 44% of the reports 
were for female patients for PV and SV, respectively. The median dose reported was 20 mg for 
PV and 40 mg SV.  The median reported time to onset of rhabdomyolysis was eight months for 
PV and 5.5 months for SV.  A temporal dose increase was reported in zero out of 25 (0%) PV 
cases and 22 out of 118 (19%) SV cases. A switch from one statin to another statin within 60 
days of the event was reported in one out of 25 (4%) PV cases and 11 out of 118 (9%) SV cases.  
Five (20%) PV and 25 (21%) SV treated patients reported acute renal failure or required dialysis. 
Four patients reportedly died from events presumably related to the adverse drug reaction (two 
(8%) patients treated with PV and two (2%) treated with SV).   
Among the 25 PV and 118 SV associated cases, three (12%) and 56 (47%) reported a 
concomitant CYP3A4 inhibitor, respectively. The distribution of PV and SV cases with specific 
concomitant CYP3A4 inhibitor is shown in Table 2. Of interest, six cases associated with SV and 
one case associated with PV reported two concomitant CYP3A4 inhibitors. 
Table 3 shows the SV dose analysis stratified by the presence or absence of a concomitant 
CYP3A4 inhibitor.  Importantly, the median SV dose with and without a concomitant CYP3A4 
inhibitor was equivalent (40 mg).  However, the mean SV dose was higher (56 mg vs. 38mg) for 
cases reporting a concomitant CYP3A4 inhibitor than for cases not reporting a concomitant 
CYP3A4 inhibitor. A similar dose analysis for PV cases was not possible due to missing dose 
information among the three PV cases reporting a concomitant CYP3A4 inhibitor. A recent dose 
increase was reported was reported in 0 out of 25 (0%) PV cases and 23 out of 118 (19%) SV 
cases. 
Reporting rate analysis: The NPA Plus audit produced 83,673,000 and 120,188,000 U.S. 
dispensed retail prescriptions for PV and SV from initial marketing.15  The observed range of 
physician response for NAMCS was 63% (1999) to 73% (1993). Table 4 shows the NAMCS 
concomitant frequency data for selected CYP3A4 inhibitors and GEM. The proportion of mentions 
of PV and SV with a concomitant CYP3A4 inhibitor was 0.15 and 0.12 respectively.  For use in 
the secondary analysis, the proportion of concomitant mentions of PV and SV with concomitant 
GEM was 0.0079 and 0.0149 respectively.  Based on these data, we found the estimated US 
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population exposure for PV and SV to be approximately 83 million and 118.4 million U.S. 
dispensed prescriptions (without GEM concomitancy). The primary analysis will use these two 
numbers for calculating the AER and AERR.   
Table 5a shows the unadjusted AER analysis for PV and SV.  Twenty five cases of 
rhabdomyolysis associated with PV were identified among an estimated 83 million PV 
prescriptions yielding an AER of 3.0 cases per 10 million prescriptions.  One hundred eighteen 
cases of rhabdomyolysis associated with SV among an estimated 118.4 million SV prescriptions 
yielding an AER of 10.0 cases per 10 million prescriptions. Without adjusting for CYP3A4 inhibitor 
concomitancy, the rhabdomyolysis AERR (SV/PV) was 3.3.   
AERs and AERRs stratified by concomitant use of CYP3A4 inhibitors are shown in Table 5b. 
The AERs for PV with and without a concomitant CYP3A4 inhibitor are 2.4 and 3.1 cases per 10 
million prescriptions (AERR = 0.77). The AERs for SV with and without a concomitant CYP3A4 
inhibitor are 38.4 and 6.0 cases per 10 million prescriptions (AERR = 6.43).  Table 5b also shows 
the relative effect of SV cases to PV cases.  When stratified by CYP3A4 inhibitor, the relative 
effect (AERR) of SV/PV was 16.0 (38.4/2.4) with a concomitant CYP3A4 inhibitor and 1.9 
(6.0/3.1) without a concomitant CYP3A4 inhibitor. 
Tables 6a and 6b show the secondary analysis with concomitant statin and GEM.  Twenty 
eight PV and 159 SV spontaneous reports of rhabdomyolysis met the prespecified inclusion 
criteria. Among these cases, 3 PV and 41 SV cases reported concomitant exposure to GEM. The 
crude AERs were 3.3 and 13.2 per 10 million prescriptions for PV and SV, respectively.  
Stratifying the PV cases by concomitant GEM gave AERs of 3 and 45 per 10 million prescriptions 
with and without GEM, respectively (AERR = 15). Stratifying the SV cases by concomitant GEM 
gave AERs of 229 and 10 cases per 10 million prescriptions with and without GEM, respectively 
(AERR = 23). 
All results use the aggregate proportion of all CYP3A4 inhibitors with a concomitant statin 
(SV =0.1526, PV=0.1231). However, individual CYP3A4 inhibitor concomitancy with SV resulted 
in AER point estimates greater than the baseline AER (6.0 cases per 10 million SV Rxs without a 
CYP3A4 inhibitor) (data not shown). 
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DISCUSSION 
This descriptive analysis of rhabdomyolysis AERs and AERRs associated with PV and SV 
reveals noteworthy effect modification by CYP3A4 inhibitor concomitancy for SV but not PV 
(Table 5b). The crude AERs and AERRs (Table 5a) for SV and PV are consistent with previous 
findings. Chang et al. reported a crude reporting rate ratio of 4 (SV/PV), which approximates our 
curde AERR of 3.3 (SV/PV).15 Contrasting the crude AERR with the stratified AERR (by CYP3A4 
inhibitor concomitancy) suggests a striking interaction consistent with the different 
pharmacokinetic clearance pathways for PV and SV. 
In order to further explore the phase I interaction hypothesis, we conducted a secondary 
analysis among PV and SV reports with concomitant GEM as the interacting drug. GEM has been 
shown to inhibit Phase I metabolism (via primarily the CYP2C8 isoenzyme), Phase II metabolism 
(glucuronidation), and uptake transport (via OATP).46 In contrast to CYP3A4 inhibitors, GEM 
minimally inhibits the phase I metabolic pathway for either PV or SV.  Thus, we hypothesized no 
effect modification for PV and SV with concomitant GEM. Supporting this hypothesis, the results 
show that although PV-GEM and SV-GEM concomitancy is associated with elevated AERs 
(Table 6b), the relative effect (AERR) is seemingly non-differential between PV (AERR = 15) and 
SV (AERR = 23) with versus without GEM.  
The statin-GEM findings provide another level of evidence to support the effect modification 
found in the primary analysis.  While GEM exhibited interaction potential with cerivastatin 
plausibly through both metabolic (CYP2C8) and uptake transport (OATP) pathways, it does not 
possess PK characteristics that make it likely to differentially interact with PV or SV.  Although 
both PV and SV rely on hepatic uptake transport via OATP, neither drug undergoes phase I 
metabolism by CYP2C8. Thus, the non-differential finding with concomitant GEM is expected and 
reassuring.  
As shown in Table 3, stratification by statin dose provides inconclusive results for SV and PV 
associated rhabdomyolysis when adjusted for a concomitant CYP3A4 inhibitor.  Despite skewed 
data with large variances, SV-associated cases have the same median dose regardless of 
CYP3A4 concomitancy.  However, for PV cases, it is not possible to compare the impact of 
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increasing dose between the two strata due to missing dose information for cases reporting 
CYP3A4 concomitancy.  Further analyses need to be conducted to fully evaluate the potential 
interaction by statin dose given missing and inconsistent data inherent to voluntary, spontaneous 
reports. 
Although the findings from this study are consistent with a robust and selective interaction 
between SV and CYP3A4 inhibitors, the study has limitations which should be highlighted.  
Spontaneous AERs are believed to underestimate actual incidence rates substantially.  This 
occurs because the adverse event must be: diagnosed, attributed to a drug, reported to the FDA 
or to the manufacturer, and documented with specific information in order to meet study inclusion 
criteria.  Furthermore, the discrepancy between reporting rates and incidence rates may increase 
as physicians become more comfortable identifying and managing statin-related adverse drug 
reactions.   
Other limitations involve the quality of case reports. Although the MedWatch form has 
changed little during the study period, the content of each case report may differ considerably 
from report to report. This difference is further complicated by the reporting source, e.g., 
pharmaceutical manufacturer or health care provider.  In order to improve study precision, we 
excluded cases reported by non-health care providers and recorded the reporting source as a 
potential confounding variable. Fortunately, there was near perfect balance of reports reported to 
the FDA by the pharmaceutical manufacturers for SV and PV.  However, this does not rule out 
differential protocols for managing adverse event reporting between the manufacturers.   
Further limitations should be considered regarding the drug utilization estimates (the 
denominator used in calculating the adverse event reporting rates (AER)). This is particularly true 
for the proportion of concomitant CYP3A4 inhibitor therapy with PV (0.15) and SV (0.12). These 
concomitant frequency proportions were derived from NAMCS, a weighted and projected annual 
national survey of approximately 2,000 office-based physicians in the US. There may be 
substantial variability for infrequent events - such as infrequently used drug products.  This 
variability is therefore increased in the assessment of coincident events, such as the concomitant 
use of two specific agents (e.g., a rarely used drug product in conjunction with a statin).  
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Furthermore, NAMCS may not capture drugs prescribed by non-NAMCS participating 
physicians, particularly specialists.  Section 9 of the NAMCS survey requests information on 
“medications that were ordered, supplied, administered or continued during this visit.”  As this 
statement is subject to interpretation, one practice may record all patients medications while 
another may record only those ordered, supplied, administered or continued during that specific 
office visit.  For example, if a NAMCS participating primary care physician records the statin 
therapy he initiated (or refilled), but does not record the antifungal therapy prescribed by a 
dermatologist, the concomitancy therapy is not recorded.  This potential inconsistency may 
underestimate the true proportion of concomitant statin-CYP3A4 inhibitor therapy.  
Underestimating concomitancy (statin-CYP3A4 inhibitor or statin-GEM concomitancy) would 
overestimate the reporting rates and reporting rate ratios.  To better understand the impact of a 
potential underestimation of the proportion of statin-CYP3A4 inhibitor concomitancy, we 
conducted a sensitivity analysis for different proportions of statin-CYP3A4 inhibitor concomitancy. 
Table 7 shows an inverse relationship between the concomitant frequency proportion and the 
AERs and AERRs. That is, if the concomitancy estimate is underestimated, the reporting rates 
and reporting rate ratios may be biased.  
Conclusion 
Despite these limitations, our findings are consistent with increased risk of rhabdomyolysis 
during concomitant use of SV, a CYP3A4 substrate statin, and a CYP3A4 inhibitor. Additionally, 
the results support observations regarding muscle toxicity in SV clinical trials with concomitant 
CYP3A4 inhibitors. Further analytic research is warranted to fully elucidate these findings. 
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TABLES 
AERS TABLE 1 
Case attributes Pravastatin (n=25) Simvastatin (n=118)
Age (years) n=16 n=102
range 24 - 79 27-93
median 66 66
mean 61 64
Sex n=22 n=110
female 12 48
male 10 62
unknown 3 8
Weight (lbs) n=5 n=48
mean 171 181
median 181 173
Reported statin switch n=25 n=118
number switched (%) 1 11
Concomitant meds n=14 n=106
median number 5 4
standard deviation 3 3
Reaction onset (months) n=15 n=82
range 0.2 - 33 0.1 - 90
median 8 5.5
mean 12 13
Outcome variables n=25 n=118
hospitalized 25 118
death 2 2
CK median 12,300 19,240
CK range 1,076 - 700,000 761 - 625,333
acute renal failure or dialysis 5 25
Report characteristics n=25 n=118
manufacturer report 17 81
report year (median) 1997 1999
report year range 1992-2001 1993-2001
Table 1. Demographic and clinical attributes of domestic spontaneous 
reports of rhabdomyolysis associated with pravastatin and simvastatin*
* Excluding cases with concomitant gemfibrozil and gemfibrozil prescriptions  
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AERS TABLE 2 
CYP3A4 inhibitor(s)
 Number of 
simvastatin 
cases
Number of 
pravastatin 
cases
Statin plus 1 reported inhibitor
clarithromycin 10
mibefradil 10
verapamil 8
nefazodone 6
cyclosporine 5
diltiazem 5 2
itraconazole 3
erythromycin 2
ketoconazole 1
Statin plus 2 reported inhibitors
cyclosporine, diltiazem 1 1
cyclosporine, itraconazole 1
cyclosporine, ketoconazole 1
cyclosporine, mibefradil 1
cyclosporine, verapamil 1
mibefradil, verapamil 1
Total 56 3
Table 2. Domestic spontaneous reports of rhabdomyolysis 
associated with simvastatin or pravastatin and concomitant 
CYP3A4 inhibitors
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AERS TABLE 3 
SV PV SV PV SV PV
Reports of rhabdomyolysis n=118 n=25 n=56 n=3 n=62 n=22
Number reporting dose (%) 95 (80) 13 (52) 46 (82) 0 49 (79) 13 (52)
Dose range (mg) 5-160 20-40 5-160 n/a 5-80 20-40
Mean / median / sd  (mg) 47 / 40 / 31 26 / 20 / 10 56 / 40 / 34 n/a 38 / 40 / 27 26 / 20 / 10
Reported taking max* statin dose ( 32 (34) 4 (31) 20 (43) n/a 12 (24) 4 (31)
Recent statin dose increase (%) 23 (19) 0 (0) 13 (23) n/a 10 (16) 0 (0)
* Max dose refers to the maximum FDA approved dose in the United States (pravastatin = 40mg; simvastatin = 80mg)
Table 3. Dose analysis for domestic spontaneous reports of rhabdomyolysis associated with pravastatin and 
simvastatin stratified by concomitant use of a selected CYP3A4 inhibitor
All cases w/ CYP3A4 inhibitor w/o CYP3A4 inhibitor
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AERS Table 4 
Selected CYP3A4 inhibitors Pravastatin Simvastatin
clarithromycin 0.80% 0.01%
erythromycin 0.77% 0.19%
cyclosporine 0.52% 0.04%
mibefradil 0.06% 0.01%
verapamil 5.02% 3.80%
diltiazem 8.01% 7.53%
nefazodone 0.20% 0.27%
itraconazole/ketoconazole 0.28% 0.39%
Combined total 15.26% 12.31%
Fibrates
gemfibrozil 0.79% 1.49%
Table 4.  Proportion of concomitant mentions of pravastatin or 
simvastatin and selected CYP3A4 inhibitors or gemfibrozil in the 
National Ambulatory Care Survey (NAMCS), 1993-2001
 
AERS TABLE 5A 
Pravastatin Simvastatin AERR
25 118
83,012,000 118,397,000
3.0 10.0
Table 5a. Reporting rates (AER) and ratios (AERR) for domestic spontaneous 
reports of rhabdomyolysis associated with pravastatin and simvastatin*
All cases
Cases of Rhabdomyolysis
3.3
Rxs (1991-2001)
AER (per 107 Rxs)
* Excluding cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
 
AERS TABLE 5B 
w/ CYP3A4 
inhibitor
w/o CYP3A4 
inhibitor
AERR
3 22
12,668,000 70,344,000
2.4 3.1
Cases of Rhabdomyolysis 56 62
14,575,000 103,822,000
38.4 6.0
Table 5b. Reporting rates (AER) and ratios (AERR) for domestic spontaneous 
reports of rhabdomyolysis associated with pravastatin and simvastatin stratified 
by concomitant use of a selected CYP3A4 inhibitor*
Pravastatin cases
Cases of Rhabdomyolysis
0.77
Rxs (1991-2001)
AER (per 107 Rxs)
Simvastatin cases
6.43
Rxs (1991-2001)
AER (per 107 Rxs)
* Excluding cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
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AERS TABLE 6A 
Pravastatin Simvastatin AERR
28 159
83,673,000 120,188,000
3.3 13.2
Table 6a. Reporting rates (AER) and ratios (AERR) for domestic spontaneous 
reports of rhabdomyolysis associated with pravastatin and simvastatin**
All cases
Cases of Rhabdomyolysis
4Rxs (1991-2001)
AER (per 107 Rxs)
** Including cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
 
AERS TABLE 6B 
w/ gemfibrozil w/o gemfibrozil AERR
Cases of Rhabdomyolysis 3 25
Rxs (1991-2001) 661,000 83,012,000
AER (per 107 Rxs) 45.4 3.0
Cases of Rhabdomyolysis 41 118
Rxs (1991-2001) 1,791,000 118,397,000
AER (per 107 Rxs) 228.9 10.0
** Including cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
15
23
Table 6b. Reporting rates (AER) and ratios (AERR) for domestic spontaneous 
reports of rhabdomyolysis associated with pravastatin and simvastatin stratified 
by concomitant use of gemfibrozil**
Pravastatin cases
Simvastatin cases
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AERS TABLE 7 
w/ CYP3A4 
inhibitor
w/o CYP3A4 
inhibitor
w/ CYP3A4 
inhibitor
w/o CYP3A4 
inhibitor
Pravastatin (n=3) (n=22)
0 83,012,000 0% - 2.7 -
4,150,600 78,861,400 5% 7.2 2.8 2.6
8,301,200 74,710,800 10% 3.6 2.9 1.2
12,667,631 70,344,369 15.26% 2.4 3.1 0.8
16,602,400 66,409,600 20% 1.8 3.3 0.5
20,753,000 62,259,000 25% 1.4 3.5 0.4
Simvastatin (n=56) (n=62)
0 118,397,000 0% - 5.2 -
5,919,850 112,477,150 5% 94.6 5.5 17.2
11,839,700 106,557,300 10% 47.3 5.8 8.1
14,574,671 103,822,329 12.31% 38.4 6.0 6.4
17,759,550 100,637,450 15% 31.5 6.2 5.1
23,679,400 94,717,600 20% 23.6 6.5 3.6
29,599,250 88,797,750 25% 18.9 7.0 2.7
*** excluding cases w ith concomitant gemfibrozil and gemfibrozil prescriptions
Table 7. Sensitivity analysis of statin-CYP3A4 inhibitor concomitancy***
* AER is the number of reports/ the number of estimated prescriptions (per 10 million prescriptions)
** AERR is calculated as the reporting rate w / a CYP3A4 inhibitor/ the reporting rate w /o a CYP3A4
Number of prescriptions AER*Concomitant 
%
AERR**
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ABSTRACT 
Purpose: The propensity score was developed to control for differences in observed covariates 
for two treatment groups. In drug-drug interaction studies, there are usually more than two non-
ordered exposure categories.  The theoretical framework for the multinomial score was previously 
described. However, simulation studies to evaluate the performance characteristics of different 
propensity score methods in analyzing multiple, non-ordered exposure categories have not been 
published. This is important for empiric investigations where the presence and quantity of model 
misspecification is rarely known.  
Methods: In a simulated drug-drug interaction study, we evaluated the statistical performance of 
multiple multinomial and binary propensity score approaches of confounding adjustment. Monte 
Carlo simulations were performed on a synthetic cohort with a binary outcome (Y), three binary 
exposure variables (A1, A2, A3=A1*A2), and three covariates (X1, X2, X3).  We compared percent 
bias, coverage probability, and precision (MSE) of the interaction ratio parameter from four 
different binary propensity score adjusted models and the multinomial propensity score adjusted 
model.  We also compared the relative performance of each propensity score approach to an 
unadjusted model (the null model) and the correctly specified multivariate model (the MV model). 
We evaluated statistical performance under a variety of scenarios typical of drug safety research. 
To achieve this, we determined baseline coefficient values for each parameter from those found 
in drug safety research.  Holding baseline parameters constant, we varied individual parameters 
one at a time to assess performance characteristics under a variety of scenarios. We varied the 
sample size, the prevalence of exposure, the strength of association between exposure variables, 
the interaction between one exposure variable and a covariate, the outcome incidence, the 
strength of the interaction ratio, and propensity score form.   
Results: The results from these drug interaction simulations show the multinomial propensity 
score adjusted model was the least biased, had the greatest coverage probability, and best 
precision compared to four different binary propensity score adjusted models. For all scenarios, 
the multinomial propensity score model demonstrated consistently superior statistical 
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performance - similar to the rarely identifiable MV model. The multinomial propensity score was 
the least biased in the presence of model misspecification.  
Conclusion: Investigators conducting drug-drug interaction research should consider using the 
multinomial propensity score approach to adjust for confounding. 
 
 
26
INTRODUCTION 
Inferring the causal effect of one or more treatments that are not randomly assigned is often 
the goal of empiric observational research.  However, absent random treatment assignment, the 
researcher has no assurance that patients receiving different treatments have similar distributions 
of factors that influence outcome occurrence.  Therefore, researchers must make every effort to 
account for inter-patient differences in pre-treatment (baseline) characteristics, using appropriate 
statistical methodology.  
One approach to account for (or balance) patient baseline characteristics is to use the 
propensity score, which is the predicted probability of treatment conditional on the observed 
(baseline) covariates.58 The propensity score is a one dimensional covariate used to describe a 
multidimensional covariate matrix, and has been shown to be particularly useful when studying 
rare outcomes with many potential confounders, where it is not feasible to include all of the 
confounders in the statistical models.59  The propensity score was originally developed to control 
for differences in observed covariates for two treatment groups (i.e., for a binary exposure).58   
Methods have been described for deriving and using the propensity score for ordered 
exposure categories (e.g., in dose response analyses).60-62  However, little research has been 
conducted using the propensity score to balance the predicted probability of treatment for more 
than two, non-ordered treatment categories.  Imai et. al and Imbens et. al described the 
theoretical framework for the multinomial propensity score (PSm).61, 63 They showed the predicted 
probability of more than two treatments could be derived given observed covariates. Huang and 
colleagues applied the PSm in a cross-sectional study of patient satisfaction with asthma care 
(the outcome) associated with twenty different physician groups (the multinomial exposure).64 
They showed the multinomial propensity score approach balanced the covariates among the 
different physician groups.  While this study showed covariate balancing properties of the PSm, 
the authors didn't conduct simulations to investigate further PSm performance characteristics 
compared to other binary PS approaches or with correlated exposures.   
The multinomial propensity score approach has potential applications in numerous settings 
where the exposure has more than two categories.  A drug-drug interaction (DDI) study is one 
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example of a multinomial exposure.  DDI studies often have more than two unordered exposure 
categories made up of combinations of an object drug and a precipitant drug. An object drug is a 
drug that is affected by a drug-drug interaction (e.g., reduced metabolism and increased 
bioavailability). The object drug is often a substrate for a specific hepatic enzyme.  A precipitant 
drug is a drug that catalyzes the drug-drug interaction through inhibition of the specific hepatic 
enzyme. Each patient may be in one of four exposure categories.  The exposure categories 
include: (i) the object drug only, (ii) the comparator object drug only, (iii) the object drug and the 
precipitant drug, and (iv) the comparator object drug and the precipitant drug.  Importantly, there 
is no assumed ordering to these four exposure categories.  Using this type of DDI study 
framework, we propose to evaluate the statistical performance of different propensity score 
methods (multinomial and binary) through simulation.    
No applied methodologic research using simulations to evaluate different propensity score 
methods in multiple, non-ordered exposure categories have been published.  This study 
evaluates relative bias, coverage probability, and mean squared error associated with different 
binary and multinomial propensity score methods. We simulated scenarios relevant to drug safety 
investigations.  By evaluating each propensity score method under different scenarios, we 
provide drug-drug interaction researchers with a broadly applicable tool that will guide their choice 
of confounding adjustment method.  The results from this study provide guidance regarding the 
validity of the multinomial propensity score.  If the multinomial propensity score adequately 
reduced bias under the scenarios evaluated, we will use this method for confounding adjustment 
in the confirmatory drug-drug interaction cohort study.   
METHODS 
For the simulated drug-drug interaction study, the primary effect estimate is the interaction 
between the object drug and the precipitant drug. The interaction term is referred to as the 
interaction ratio (I*R). The I*R is a ratio of two ratios.  Under the proposed DDI study, the I*R 
compares the association of the object drug with the precipitant drug to the association of the 
comparator object drug with the precipitant drug, adjusted for the effect of the object drug and 
comparator object drug without the precipitant drug.  This contrast represents the relative effect of 
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the object drug with a concomitant precipitant drug compared to the comparator object drug with 
a concomitant precipitant drug independent of the individual effects of either the object drug or 
the comparator object drug alone.  Since we are interested in the effect of the drug-drug 
interaction independent of the effects of the object/comparator object drugs alone, this 
investigation will focus on the I*R. 
Simulation approach to creating synthetic cohorts: 
We used 1,000 simulated data sets to evaluate the performance of multinomial and binary 
propensity score methods. We used Stata version 11.1 to perform all Monte Carlo simulations.  
We used the random number generator provided by Stata. The methods for generating normal 
(Gaussian) and uniform random numbers in Stata were derived by Knuth (1998) 65; Marsaglia, 
MacLaren, and Bray (1964); and Walker (1977). 
Monte Carlo simulations were performed on the synthetic cohort of patients with a binary 
outcome (Y), three binary primary exposure variables (A1, A2, A3=A1*A2), and three covariates 
(X1, X2, X3).   The binary outcome variable (Y), represents the presence or absence of the 
outcome (Y=1: outcome present; Y=0: outcome absent). The binary exposure variable A1 
represents exposure to either the object drug (A1=1) or the comparator object drug (A1=0). The 
binary exposure variable A2 represents exposure to the precipitant drug (precipitant drug present 
or absent: A2=1 or A2=0). The binary exposure interaction variable (A3) represents the interaction 
between A1 and A2 (A1*A2).  When A3=1 cohort members are exposed to the object drug (A1=1) 
and the precipitant drug (A2=1).  When A3=0 cohort members are exposed to: the object drug 
without the precipitant drug (A1=1, A2=0), the comparator object drug with the precipitant drug 
(A1=0, A2=1), or the comparator object drug without the precipitant drug (A1=0, A2=0).  
To evaluate the multinomial propensity score, we generated a multinomial exposure variable 
(A4). This non-ordered, categorical variable was derived from the four possible exposure 
categories for A1 and A2. The four categories of A4 are: A4=1 (A1=1,A2=1); A4=2 (A1=1,A2=0); 
A4=3 (A1=0,A2=1);  A4=4 (A1=0,A2=0). We generated the covariates X1 and X2 as random 
continuous variables (standard normal mean 0; standard deviation 1). We generated X3 as 
random binary variable (1,-1) with p(1)=0.0).  To compare to statistical performance of the 
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multinomial propensity score, we generated several binary propensity scores from A1, A2, and A3 
(described below). 
We generated associations among the exposure variables (A1, A2, A3) and covariates (X1, 
X2, X3) to approximate those found in medical research. For the exposure variables and 
covariates, we varied the coefficients to evaluate statistical performance under a variety of 
conditions.  
Description of base equations: 
In simulation studies the investigator builds equations where associations among the 
outcome, exposure, and confounding variables are known (because these associations are 
determined by the investigator).  We used three base equations, each with investigator 
determined coefficients (see base equations below). Using base equation Y as the true outcome 
model, we evaluated how closely each propensity score method estimated the interaction ratio 
(λ3) in this model.  Below we present base equations used to derive A1 (the object 
drug/comparator object drug), A2 (the precipitant drug present/absent), and Y (the binary outcome 
yes/no).  In base equation A1 we determined the associations among A1 and the covariates X1, 
X2, X3. In base equation A2 we determined the associations among A2 and the exposure variable 
A1, the covariates X1, X2, X3, and the A1*X1 interaction. In base equation Y we determined the 
association among the outcome variable (Y) and the exposure variables A1, A2, A3 and the 
covariates X1, X2, X3.  
Base Equation A1 - object/comparator drug model 
Logit p(A1=1) = β0 + β1X1 + β2X2 + β3X3 
Base Equation A2 - precipitant drug model 
Logit p(A2=1) = θ0 + θ1A1 + θ2X1+ θ3X2 + θ4X3 + θ5(A1*X1) 
Base Equation Y - true outcome model 
Logit p(Y=1) = λ0 + λ1A1 + λ2A2 + λ3A3 + λ4X1+ λ5X2 + λ6X3 
Baseline values: 
In order to evaluate the performance of each propensity score, we first determined baseline 
values for each coefficient in the base equations.  Baseline coefficient values were selected 
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based on the approximate values in an empiric drug interaction study conducted by the principal 
investigator (data not yet published).  Holding baseline values constant, we varied specific 
coefficients (one at a time), to evaluate relative bias, coverage probability, and mean squared 
error (MSE) under a variety of conditions.  The baseline sample size was set to 100,000 synthetic 
cohort members.   
In base equation A1, the baseline coefficients were set to the following values. 
Logit Pr(A1=1) = β0 + β1X1 + β2X2 + β3X3 
Baseline coefficients: β0=1.0;  β1=1.0;  β2=0.0; β3=1.0 
The baseline constant (β0) was set to 1.0. This baseline value set the proportion of A1=1 to 
0.65 and A1=0 to 0.35.  The baseline associations for A1 with X1, X2, and X3 were set to β1=1.0, 
β2=0.0, β3=1.0, respectively.   
In base equation A2, the baseline coefficients were set to the following values. 
Logit Pr(A2=1) = θ0 + θ1A1 + θ2X1+ θ3X2 + θ4X3 + θ5(A1*X1) 
Baseline coefficients: θ0=-1.0; θ1=0.2; θ2=0.0; θ3=1.0; θ4=1.0; θ5=0.2 
This baseline constant of -1.0 set the proportion of A2=1 to 0.35 and A2=0 to 0.65. The 
baseline association between A1 and A2 (θ1) was set to 0.2. This represents a modest association 
between the object drug and precipitant drug.  The baseline associations for A2 with X1, X2, and 
X3 were set to θ2=0.0, θ3=1.0, θ4=1.0, respectively.  The baseline interaction between A1 and X1 
(θ5) was set to 0.2. This represents a weak interaction between the covariate X1 and the object 
drug A1.  
In base equation Y, the coefficients were set to the following values. 
Logit p(Y=1) = λ0 + λ 1A1 + λ 2A2 + λ 3A3 + λ 4X1+ λ 5X2 + λ 6X3 
Baseline coefficients: λ0=-2; λ 1=0.1; λ 2=0.1; λ 3=0.4; λ 4=1.0; λ 5=1.0; λ 6=1.0 
The baseline constant of -2.0 (λ0=-2.0) set the proportion of Y=1 to 0.2 and Y=0 to 0.8. The 
baseline association between A1 and Y was set to 0.1 (λ1=0.1). The baseline association between 
A2 and Y was set to 0.1 (λ2=0.1). The baseline association between A3 and Y was set to 0.2 
(λ3=0.4). The baseline association between the covariates (X1, X2, and X3) and the outcome Y 
was set to1.0.   
 
 
31
Statistical properties evaluated: 
Relative bias was our primary measure of statistical performance.  Relative bias reflects the 
difference between the estimated λ3 value and the true λ3 value. We expressed relative bias as a 
percentage [(estimated λ3 - true λ3)/ true λ3)*100]. Positive (negative) percent bias indicated an 
overestimation (underestimation) of the association.  Zero percent bias values indicated no bias. 
Ninety five percent confidence intervals for percent bias were derived using the bootstrap 
percentile method.  Based on 1000 simulated λ3 estimates, percent bias was calculated. 
We also evaluated coverage probability and mean squared error (MSE) of the estimated 
value of λ3.  Coverage probability was estimated as the proportion of times the confidence interval 
for the estimated value of λ3 included the true value of λ3. Precision was estimated by determining 
the MSE value of the estimated value of λ3 over 1000 Monte Carlo repetitions. We determined the 
MSE by adding the average bias squared and the average bias standard deviation squared 
([average bias]2 + [average bias standard deviation]2). 
Propensity score methods to be compared: 
We evaluated the performance of the multinomial propensity score and other binary 
propensity scores methods in the setting of a hypothetical drug interaction study. Because we are 
interesting in studying a four level, non-ordered exposure; the multinomial propensity score was 
derived using multinomial logistic regression (MLR).63 MLR is an adaption of binary logistic 
regression for multiple, non-ordered outcomes. Using MLR, the multinomial propensity score was 
derived by regressing the covariates X1, X2, & X3 on the categorical (four level) exposure variable 
A4. MLR compares each exposure category of A4 (1, 2, 3, and 4) through a combination of binary 
logistic regressions. As with traditional propensity score methods, MLR is followed by arithmetic 
transformation of odds (probability/1-probability) into the predicted probability (odds/1+odds) of 
being in one of the following exposure categories: 1 vs 4, 2 vs 4, and 3 vs 4.  Category 4 was set 
as the base level for MLR. The probability of being in a particular exposure category (1, 2, 3, or 4) 
is a quantitative representation of the joint distribution of each exposure category given the set of 
covariates. We derived the multinomial propensity score (PS4) by determining the predicted 
probability of each A4 category given X1, X2, & X3. Functionally this equates to estimating the 
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following  conditional probabilities (i) Pr(A4=1| X1, X2, X3), (ii) Pr(A4=2| X1, X2, X3), (i) Pr(A4=3| X1, 
X2, & X3), (iii) Pr(A4=4| X1, X2, & X3). Because the cumulative sum of these four probabilities is 
one, confounding adjustment with PS4 uses three of the four probabilities.  
For comparison with the multinomial propensity score (PS4), we used logistic regression to 
derive the predicted probability of other binary exposure variables A1, A2, and A3 given X1, X2, and 
X3.  Functionally this equates to estimating the following conditional probabilities: Pr(PS1: A1=1| 
X1, X2, X3), Pr(PS2: A2=1| X1, X2, X3), and Pr(PS3: A3=1| X1, X2, X3). Below is a summary 
derivation of each propensity score evaluated included in this investigation.  
PS1:  logit Pr(A1=1) = ρ01 + ρ11X1 + ρ21X2 + ρ31X3 
PS2:  logit Pr(A2=1) = ρ02 + ρ12X1 + ρ22X2 + ρ32X3 
PS3: logit Pr(A3=1) = ρ03 + ρ13X1 + ρ23X2 + ρ33X3 
PS4:  mlogit  Pr(A4=1): ρ041 + ρ141X1 + ρ241X2 + ρ341X3 
 mlogit  Pr(A4=2): ρ042 + ρ142X1 + ρ242X2 + ρ342X3 
 mlogit  Pr(A4=3): ρ043 + ρ143X1 + ρ243X2 + ρ343X3 
 mlogit  Pr(A4=4): ρ044 + ρ144X1 + ρ244X2 + ρ344X3 
PS12: PS1 & PS2 
We evaluated each of these models in the presence of weak model misspecification.  
Evaluating statistical performance in the presence known model misspecification, informs us 
about the effectiveness of the different confounding adjustment approaches under this common 
(and often unknown) condition. It is often the case in empiric research that model misspecification 
occurs.  Under model misspecification we did not account for the weak interaction between A1 
and X1 (A1*X1). The A1*X1 interaction is depicted in base equation A2.  
Propensity score form: 
We evaluated each propensity score using three approaches:  spline, categorical, and 
continuous covariates. Categorical propensity scores were derived using quintiles of the predicted 
probabilities. Spline propensity scores were derived through cubic spline regression with five 
interior knot points placed at quintiles of the estimated propensity score. Continuous propensity 
scores used the linear form of the predicted probabilities. In general, spline and categorical 
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covariates are useful when the relationship between the dependent variable (Y) and the 
independent variables is not linear. Regression splines also provide flexibly to model a 
nonparametric relationship between the propensity score and outcome variable. We used the 
spline propensity score adjustment as the baseline form.  While propensity scores stratification 
and matching are commonly used methods, applications of these methods with a multinomial 
exposure have not been developed.    
Outcome models: 
All propensity score adjusted outcome models used logistic regression with three exposure 
variables (A1, A2, A3) and the propensity score (E[Y| A1, A2, A3, PS]). We refer to propensity score 
outcome models using PS* to indicate that we evaluated each propensity score (described 
above). We compared each propensity score outcome model to an unadjusted model (the null 
model) and a correctly specified multivariable (MV) model. The null model included only exposure 
variables regressed on Y (E[Y| A1, A2, A3]). The null model allowed us to quantify bias without 
covariate adjustment.  The MV model included each exposure variable and the three covariates 
regressed on Y (E[Y| A1, A2, A3, X1, X2, X3]).  In empiric research, the correctly specified MV 
model is rarely known.  It is presented in this study to illustrate the relative performance of the 
propensity score methods to the performance of the correctly specified model. We present bias, 
coverage probability, and MSE for the interaction ratio (the estimated value of λ3) from the null 
model, the MV model, and each propensity score model.  The five propensity score models were 
independently evaluated in PS*. The outcome models are presented below.  
Null outcome model:  Logit Pr(Y=1) = ξ0 + ξ1A1 + ξ 2A2 + ξ 3A3 
MV outcome model:  Logit Pr(Y=1) = ω0 + ω 1A1 + ω 2A2 + ω 3A3 + ω 4X1 + ω 5X2 + ω 6X3 
PS* outcome model: Logit Pr(Y=1) = φ0 + φ1A1 + φ 2A2 + φ 3A3 + φ 4PS*  
Diagnostic evaluation of propensity score balance: 
In empiric investigations, with one "real" dataset, researchers commonly evaluate the 
distribution of propensity scores for each treatment group.  This is done to evaluate balance 
between exposed and unexposed individuals given their respective vector of covariates. The 
primary reason to check propensity score balance is to evaluate the assumption of positivity.  
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Positivity exists when exposed and unexposed individuals exist at every level of each confounder.  
While the propensity score does not tell you if there are exposed and unexposed at every level of 
each confounder, it provides a composite covariate vector which summarizes the probability of 
treatment.  Assuming no gross positivity violations, one expects the PS distributions (for exposed 
and unexposed) to have some degree of overlap. The proportion of overlap informs the 
investigator about the heterogeneity of the composite covariate vector in each treatment group. In 
an extreme example, if the distributions of propensity scores, for exposed and unexposed, have 
no overlap, an excess in covariate heterogeneity suggests these two groups are not comparable.  
In order to evaluate PS balance, we present quintile box plots for each derived propensity 
score quintile.  Visual inspection of quintile box plots depicts the composite covariate overlap at 
each propensity score quintile for each exposure category.  For the binary propensity scores 
(PS1, PS2, PS3), this equates to evaluating the composite covariate distribution at each 
propensity score quintile for exposed and unexposed synthetic cohort members.  For the 
multinomial propensity score (PSm), this equates to evaluating the composite covariate 
distribution for each propensity score quintile at each of the four exposure categories. Because 
PSM is comprised of the predicted probability of four exposure categories (i.e., Pr(A4=1), 
Pr(A4=2), Pr(A4=3), and Pr(A4=4)),  we present quintile box plots for each exposure category.   
Scenarios evaluated (seven simulation studies): 
To evaluate the statistical performance of different propensity score methods, we varied 
seven different parameters - holding the other baseline values constant. The parameters we 
varied are described below.  
Confounding:   We evaluated statistical performance over a spectrum of confounding by 
changing the associations between the covariates (X1, X2, and X3) and the outcome (Y).  In the 
true outcome model (base equation Y), we evaluated beta coefficients at 0.0, 0.4, 0.7, 1.0, and 
1.39. These values range from no confounding to very strong confounding.  For all confounding 
strengths, the associations among the exposure variables (A1 and A2) and the covariates (X1, X2, 
and X3) were fixed at the baseline values.   
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Sample size: We evaluated three sample sizes of 50,000, 100,000, and 150,000 synthetic 
cohort members. These sample sizes were chosen to emulate typical drug safety data, to avoid 
finite sample bias, as well as to permit the study of both common and rare events.   
Prevalence of exposure to the precipitant drug: We evaluated three scenarios for the 
prevalence of exposure to the precipitant drug (A2=1). By varying the θ0 coefficient (from base 
equation A2), we determined the proportion of the synthetic cohort exposed to the precipitant drug 
A2 (A2=1).  We evaluated the following three proportions: 0.35 (θ0= -1.0), 0.20 (θ0= -2.0), and 0.10 
(θ0= -3.0). 
Association between object drug and precipitant drug: We varied the association between 
the object drug (A1) and the precipitant drug (A2) using θ1 (from base equation A2). This allowed 
us to evaluate each propensity score method in the presence of a null (θ1=0), a moderate 
(θ1=0.7), and a strong (θ1=1.39) association. This is equivalent to evaluating different proportions 
of concomitant exposure to A1 and A2.  
Interaction between the object drug and the covariate: We varied the interaction between the 
object drug (A1) and the covariate X1 using θ5 from base equation A2. Varying this association 
allowed us to understand how each propensity score method performed in the presence of a null 
(θ5=0), a moderate (θ5=0.4), or strong (θ5=0.7) model misspecification.  
Incidence of the outcome: We varied the proportion of synthetic cohort members having the 
outcome (Y=1). This allowed us to understand how each propensity score method performed 
under different incidences of the outcome.  We evaluated each method with the outcome 
incidence (Y=1) set at 0.2 (λ0= -2.0), 0.1 (λ0= -3.0), and 0.05 (λ0= -4.0). Given the work by 
Cepeda et. al. (ref), the incidence of the outcome may be an important characteristic in 
determining the performance of each method.   
Association between the interaction ratio with the outcome: We varied the strength of 
association between the interaction term (λ3) and the outcome (Y).  This allowed us to understand 
how each propensity score method performed in the presence of a weak (λ3=0.3), a moderate 
(λ3=0.6), or a strong (λ3=0.9) association. Depending on the strength of the association between 
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the interaction term and the outcome; it is plausible that the performance of each propensity 
score method will vary based on this association.   
Propensity score form:  Using the baseline coefficient values describe above, we evaluated 
the performance of each propensity score as a continuous, spline, and categorical covariate. 
RESULTS 
The results from the seven simulation studies are presented in Figures and Tables 1-7. 
Under each scenario evaluated, the multinomial propensity score model (PS4) demonstrated 
superior statistical performance compared to the binary propensity score models (PS1, PS2, PS3, 
PS12). Statistical performance of the PS4 model was similar to that of the MV model. As 
previously mentioned, it is rarely feasible to fit the MV model. Thus, the ability of the PS4 model 
to achieve similar performance is important.  
Confounding scenarios: Figures 1a, 1b, and Table 1 show the performance of each model 
over the spectrum of confounding (no confounding to very strong confounding).  The null model is 
increasingly biased, with worsening coverage probability, and less precision (increased MSE) as 
the strength of confounding increased. The MV model is consistently unbiased, with excellent 
coverage probability, and consistent precision over the spectrum of confounding.  The binary 
propensity score models (PS1, PS2, PS3, and PS12) were increasingly biased, had worsening 
coverage probability, and became less precise as the strength of confounding increased. Over 
the spectrum of confounding, the PS4 model demonstrated superior statistical performance 
compared to the binary propensity score models.  The PS4 model had similar percent bias, 
coverage probability, and precision to the MV model.   
Sample size variation: Figure 2 and Table 2 show the statistical performance for the three 
different sample sizes (50,000, 100,000, and 150,000).  For all models evaluated, percent bias 
was consistent with narrowing 95% confidence intervals as sample size increased. The null 
model and propensity scores models PS1, PS2, PS3, and PS12 revealed excess percent bias for 
each sample size.  The MV and PS4 models remained consistently unbiased for each sample 
size. Coverage probability for the MV and PS4 models remained consistently at 0.95. Coverage 
probability for the null and PS1, PS2, PS3, and PS12 models reduced as sample size increased.  
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The precision (MSE) of the MV and PS4 models was at least twice as precise as the binary 
propensity score models.  All models show increased precision with larger sample sizes.   
Prevalence of exposure to the precipitant drug: Figure 3 and Table 3 show statistical 
performance for three different proportions (0.35, 0.2, 0.1) of synthetic cohort members exposed 
to the precipitant drug (A2=1).  The null and binary propensity score models (PS1, PS2, PS3, and 
PS12) show increasing percent bias as the frequency of precipitant drug exposure decreases. 
The MV and PS4 models remained consistently unbiased for each proportion of precipitant drug 
exposure.  Coverage probability increased for binary propensity score models PS1, PS2, and 
PS12 and increased as the proportion of precipitant drug exposure decreased.  Coverage 
probability for the MV and PS4 models remained consistent across each proportion of precipitant 
drug exposure. For all models, precision was reduced as the proportion of precipitant drug 
exposure decreases (i.e., MSE was increased as the proportion of precipitant drug exposure 
decreased). 
Association between the object drug and the precipitant drug: Figure 4 and Table 4 show the 
statistical performance for three different associations (null, moderate, strong) between the object 
drug (A1) and the precipitant drug (A2). Across each strength of association between the object 
drug and precipitant drug, the MV and PS4 models remained unbiased, had approximately 95% 
coverage probability, and maintained a consistent level of precision (MSE).  With the 
strengthening association between the object drug and precipitant drug, percent bias and 
coverage probability for the null and the binary propensity models score trended toward 
decreasing bias and increased coverage probability.  These models also showed better precision 
(reduced MSE) as the object drug and precipitant drug association strengthened. 
Interaction between object drug and covariate: Figure 5 and Table 5 show statistical 
performance for the null, moderate, and strong interaction between the object drug (A1) and one 
of the covariates (X1). The strength of this interaction represents the amount of model 
misspecification. Under model misspecification, only the MV model is correctly specified. For 
each interaction level, the MV and PS4 models remained similarly unbiased, with near 95% 
coverage probability, and maintained a consistent level of precision. The null model showed less 
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bias, better coverage probability, and greater precision with increasing A1*X1 interaction strength.  
The binary propensity score models show varied performance across interaction levels, all with 
substantial bias and inferior coverage probability. 
Incidence of the outcome: Figure 6 and Table 6 show statistical performance under three 
incidences of outcome occurrence (Y=1). For each outcome incidence, the MV and PS4 models 
remained unbiased, with near 95% coverage probability. The null, PS1, PS2, PS3, and PS4 
models remained consistently biased over each outcome incidence. Coverage probability for the 
null and binary propensity score models was greater as the incidence of the outcome decreased. 
As evidenced by increasing MSE, precision for all models decreased with lower outcome 
incidence. 
Strength of the interaction ratio: Figure 7 and Table 7 show statistical performance for three 
interaction ratio strengths. The MV and PS4 models showed negligible bias, excellent coverage 
probabilities, and consistent precision for varied strengths of interaction ratio. Percent bias 
decreased for the null and binary propensity score models as the strength of the interaction ratio 
increased. For PS2, PS3, and PS12 coverage probability increased as the strength of the 
interaction increased.  PS1 showed reduced coverage probability with increasing interaction ratio 
strength.  Precision was increased (i.e., MSE decreased) for the null and binary propensity score 
models as the strength of the interaction ratio increased.   
Propensity score form: Figure 8 and Table 8 show statistical performance for the continuous, 
spline, and categorical propensity score forms.  For PS4, the spline form was less biased but had 
similarly good coverage probability and precision compared to the continuous and categorical 
forms.   
Balance diagnostic: The results from propensity score balance diagnostics are presented in 
Figures 9, 10, 11, 12a, 12b, 12c, and 12d.  For all propensity scores evaluated, the propensity 
score quintile box plots show sufficient covariate balance for each propensity score method to 
support the assumption of positivity. This represents similar composite covariate distributions for 
each level of the propensity score.      
Model convergence for each model evaluated was more than 99%. 
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DISCUSSION 
The results from these drug interaction simulations show the multinomial propensity score 
(PS4) was the least biased, had the greatest coverage probability, and best precision compared 
to binary propensity score methods. For all scenarios, the multinomial propensity score model 
demonstrated consistently superior statistical performance - similar to the rarely identifiable MV 
model. The multinomial propensity score was the least biased in the presence of model 
misspecification. This is important for empiric investigations where the presence and quantity of 
model misspecification is rarely known.  Superior performance of the multinomial propensity 
score was expected since each of the conditional probabilities of exposure, four each of the four 
exposure categories, given the set of covariates is determined using multinomial logistic 
regression.  Binary propensity score methods are limited since they do not account for each of 
the four exposure categories simultaneously.  
This applied simulation project builds on the theoretical approaches to the multinomial 
propensity score described by Imai et al. and Imbens et al.61, 63  In addition, these results are 
concordant with the findings of Huang et al. who showed the multinomial propensity score 
improved covariate distribution balance across twenty exposure categories compared to 
conventional methods.64 Researchers evaluating multi-level, non-ordered exposure categories, 
particularly in the setting of drug-drug interaction studies, should consider confounding 
adjustment with the multinomial propensity score. 
The simulated cohort in this investigation was nested in a cohort of object drug and 
comparator object drug users.  We did not consider scenarios where synthetic cohort members 
were truly unexposed.  However, investigators may extrapolate these results to other scenarios 
where the comparator object drug group alone (A1=0, A2=0) represents an unexposed group.  
The results of this investigation are generalizable to other studies under similar scenarios as 
those investigated in this study.  While we attempted to evaluate broadly applicable scenarios 
found in drug safety research, there may be other situations where these results will not be 
applicable.  For example, we studied statistical performance using a spectrum of confounding, 
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three incidences of the outcome, three associations between the object drug and the precipitant 
drug, three strengths of the covariate-drug interaction (A1*X1), and three associations of the drug 
interaction (A1*A2) with the outcome Y. Despite our efforts to study associations commonly found 
in drug safety research, additional research is warranted to evaluate scenarios substantially 
different from those we studied. 
 We evaluated three covariates to estimate statistical performance of different propensity 
score methods.  As demonstrated by Cepeda et al. 59, the propensity score is most 
advantageous, with regard to bias reduction, when the number of covariates is large compared to 
the number of outcomes.  Using three covariates adequately demonstrated relative statistical 
performance; however, future studies of scenarios with additional covariates with more complex 
distributions, interactions, and transformations may be beneficial for drug-drug interaction 
researchers.   
Matching and stratification on the propensity score are commonly used methods to adjust for 
confounding.  The complexity of the multinomial propensity score does not extrapolate directly to 
either matching or stratification. Methods for matching on a four level categorical exposure have 
not been developed.  This is an area for future research.  Likewise, propensity score stratification 
does not have a multinomial equivalent. Given the multinomial propensity score approach 
includes three propensity scores used in the final model, propensity score stratification would not 
provide a single overall estimate.  This strategy may not be applicable to the multinomial 
approach.  
The results from this investigation presume the assumptions for causal inference are not 
violated.  These assumptions include no unmeasured confounding, positivity, and no model 
misspecification.66 We make the assumption that, given measured covariates (X1, X2, and X3), 
there are no additional covariates that influence the association among the multi-level exposure 
and the outcome.  Investigators must make every effort to evaluate all potential covariates 
associated with the exposure and the outcome.  This is not a testable assumption. Positivity, on 
the other hand, is a testable assumption.  As previously stated, positivity exists when exposed 
and unexposed individuals exist at every level of each covariate. While this is difficult to test for 
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continuous covariates, one may evaluate positivity by examining the composite covariate 
distribution for exposed and unexposed individuals. If the distributions are similar, it may be 
assumed that positivity is achieved.  We evaluated the quintile box plots for all exposure 
categories within each propensity score quintile (for each covariate).   
Correct model specification (for logistic regression) means the relationship between the 
independent variables and the dependent variable is linear on the log scale.67 However, as 
previously described, we intentionally created weak model misspecification through the A1*X1 
interaction variable.  This was done to evaluate propensity score performance with known model 
misspecification. In empiric investigations, model misspecification may often exist, yet be 
unknown to the researcher. To provide a comprehensive evaluation (with and without model 
misspecification), we evaluated performance with a null, moderate, and strong A1*X1 interaction. 
Under all scenarios evaluated, with our without model misspecification, the multinomial propensity 
score showed superior statistical performance to binary propensity score methods. 
Conclusion 
The results from these simulation studies show the multinomial propensity score eliminated 
most bias, had greater coverage probability, and increased precision than comparator binary 
propensity score methods. The results were essentially comparable to the correctly specified MV 
model, which is rarely attainable in empiric research. Based on these results, Investigators 
studying drug-drug interactions should consider using the multinomial propensity score approach 
to adjust for confounding. 
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TABLES 
METHODS FIGURE 1 PERCENT BIAS (SPECTRUM OF CONFOUNDING) 
Percent bias by the spectrum of confounding  
(betas for assoc. b/t Y and Xs: 0.0, 0.4, 0.7, 1.0, 1.39)
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METHODS FIGURE 1A COVERAGE PROBABILITY (SPECTRUM OF CONFOUNDING) 
Coverage Probability over the spectrum of confounding
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METHODS TABLE 1 COVERAGE PROBABILITY AND MSE (SPECTRUM OF CONFOUNDING) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
0.0 0.953 0.953 0.949 0.950 0.950 0.950 0.954
0.4 0.944 0.945 0.932 0.822 0.920 0.917 0.945
0.7 0.611 0.960 0.883 0.705 0.853 0.825 0.964
1.0 0.041 0.948 0.693 0.612 0.731 0.621 0.950
1.4 0.000 0.958 0.369 0.607 0.627 0.429 0.950
Mean squared error (bias)
0.0 0.002 0.002 0.002 0.002 0.002 0.002 0.002
0.4 0.002 0.002 0.002 0.004 0.003 0.003 0.002
0.7 0.007 0.002 0.003 0.006 0.004 0.004 0.002
1.0 0.026 0.002 0.006 0.007 0.006 0.008 0.002
1.4 0.055 0.002 0.012 0.008 0.008 0.013 0.002
Methods Table 1 (coverage probability and MSE)
confounding
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METHODS FIGURE 2: PERCENT BIAS (SAMPLE SIZE) 
Sample size (50,000; 100,000; 150,000)
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METHODS TABLE 2: COVERAGE PROBABILITY AND MSE (SAMPLE SIZE) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
50,000 0.246 0.955 0.817 0.776 0.827 0.771 0.956
100,000 0.041 0.948 0.693 0.612 0.731 0.621 0.950
150,000 0.002 0.951 0.558 0.488 0.628 0.484 0.945
Mean squared error (bias)
50,000 0.028 0.004 0.008 0.010 0.008 0.010 0.004
100,000 0.026 0.002 0.006 0.007 0.006 0.008 0.002
150,000 0.025 0.001 0.005 0.007 0.005 0.007 0.001
Methods Table 2 (coverage probability and MSE)
Sample size
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METHODS FIGURE 3: PERCENT BIAS (PROPORTION A2=1) 
Proportion of cohort exposed to the precipitant drug (A2=1) 
( 0.35, 0.20, 0.10)
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METHODS TABLE 3: COVERAGE PROBABILITY AND MSE (PROPORTION A2=1) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
0.35 0.041 0.948 0.693 0.612 0.731 0.621 0.950
0.20 0.001 0.961 0.682 0.624 0.671 0.583 0.963
0.10 0.021 0.959 0.767 0.677 0.704 0.658 0.959
Mean squared error (bias)
0.35 0.026 0.002 0.006 0.007 0.006 0.008 0.002
0.20 0.050 0.003 0.008 0.010 0.009 0.011 0.003
0.10 0.068 0.005 0.010 0.015 0.015 0.017 0.005
Methods Table 3 (coverage probability and MSE)
Proportion A2 
=1
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METHODS FIGURE 4: PERCENT BIAS (ASSOC. BETWEEN THE OBJECT AND PRECIPITANT 
DRUGS) 
Association between the object drug (A1) & precipitant drug(A2) 
(null, moderate, stong)
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METHODS TABLE 4: COVERAGE PROBABILITY AND MSE (ASSOC. BETWEEN THE 
OBJECT AND PRECIPITANT DRUGS) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
null 0.023 0.952 0.705 0.655 0.725 0.594 0.955
weak 0.103 0.950 0.700 0.575 0.782 0.675 0.953
stong 0.411 0.945 0.796 0.586 0.870 0.752 0.941
Mean squared error (bias)
null 0.027 0.002 0.006 0.007 0.006 0.008 0.002
weak 0.020 0.002 0.006 0.008 0.005 0.007 0.002
stong 0.011 0.002 0.005 0.009 0.004 0.006 0.002
Methods Table 4 (coverage probability and MSE)
A1 & A2 
assoc.
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METHODS FIGURE 5: PERCENT BIAS (STRENGTH OF A1*X1 INTERACTION) 
Interaction between the object drug (A1) & covariate (X1) 
(null, moderate, stong)
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METHODS TABLE 5: COVERAGE PROBABILITY AND MSE (STRENGTH OF A1*X1 
INTERACTION) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
null 0.000 0.952 0.577 0.745 0.933 0.874 0.942
weak 0.685 0.955 0.791 0.046 0.418 0.334 0.956
stong 0.745 0.945 0.863 0.001 0.668 0.133 0.949
Mean squared error (bias)
null 0.066 0.002 0.008 0.005 0.002 0.004 0.002
weak 0.006 0.002 0.005 0.031 0.012 0.014 0.002
stong 0.005 0.002 0.004 0.054 0.007 0.022 0.002
Methods Table 5 (coverage probability and MSE)
A1 & X1 
interaction
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METHODS FIGURE 6: PERCENT BIAS (FREQUENCY OF OUTCOME OCCURRENCE (Y=1)) 
Frequency of outcome occurrence (Y=1) 
(0.20, 0.10, 0.05)
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METHODS TABLE 6: COVERAGE PROBABILITY AND MSE (FREQUENCY OF OUTCOME 
OCCURRENCE (Y=1)) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
0.20 0.041 0.948 0.693 0.612 0.731 0.621 0.950
0.10 0.086 0.950 0.806 0.732 0.788 0.701 0.953
0.05 0.474 0.953 0.916 0.808 0.853 0.801 0.950
Mean squared error (bias)
0.20 0.026 0.002 0.006 0.007 0.006 0.008 0.002
0.10 0.037 0.004 0.008 0.010 0.009 0.011 0.004
0.05 0.037 0.008 0.010 0.017 0.015 0.017 0.008
Methods Table 6 (coverage probability and MSE)
Outcome 
frequency
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METHODS FIGURE 7: PERCENT BIAS (STRENGTH OF THE INTERACTION RATIO (I*R)) 
Strength of the interaction ratio (I*R) 
(weak, moderate, strong)
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METHODS TABLE 7: COVERAGE PROBABILITY AND MSE (STRENGTH OF THE 
INTERACTION RATIO (I*R)) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
weak 0.140 0.946 0.791 0.513 0.701 0.574 0.953
moderate 0.002 0.954 0.459 0.796 0.800 0.712 0.939
strong 0.000 0.951 0.136 0.929 0.869 0.822 0.923
Mean squared error (bias)
weak 0.018 0.002 0.005 0.009 0.007 0.009 0.002
moderate 0.045 0.002 0.011 0.005 0.005 0.006 0.002
strong 0.084 0.002 0.020 0.002 0.004 0.005 0.003
Methods Table 7 (coverage probability and MSE)
Interaction 
Ratio 
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METHODS FIGURE 8: PERCENT BIAS (COVARIATE FORM) 
Propensity score form  
(continuous, spline, categorical)
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METHODS TABLE 8: COVERAGE PROBABILITY AND MSE (COVARIATE FORM) 
Null MV PS1 PS2 PS3 PS12 PS4
Coverage probability
continuous 0.041 0.948 0.942 0.877 0.683 0.267 0.918
spline - - 0.693 0.612 0.731 0.621 0.950
categorical - - 0.633 0.724 0.440 0.698 0.932
Mean squared error (bias)
continuous 0.026 0.002 0.002 0.003 0.007 0.017 0.003
spline - - 0.006 0.007 0.006 0.008 0.002
categorical - - 0.007 0.006 0.011 0.006 0.002
Methods Table 8 (coverage probability and MSE)
Propensity score 
form
 
 
 
 
 
50
 
METHODS FIGURE 9 (PS1 BALANCE DIAGNOSTIC) 
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METHODS FIGURE 10 (PS2 BALANCE DIAGNOSTIC) 
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METHODS FIGURE 11 (PS3 BALANCE DIAGNOSTIC) 
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METHODS FIGURE 12A (PS4A BALANCE DIAGNOSTIC) 
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METHODS FIGURE 12B (PS4B BALANCE DIAGNOSTIC) 
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METHODS FIGURE 12C (PS4C BALANCE DIAGNOSTIC) 
0
.1
.2
.3
.4
.5
P
r(
a4
=
=
3
)
A4=1 A4=2 A4=3 A4=4
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
 
METHODS FIGURE 12D (PS4D BALANCE DIAGNOSTIC) 
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Five key points: 
1. We studied the relative hazard of muscle toxicity, renal dysfunction, and hepatic dysfunction 
associated with statin 3A4 substrates compared to statin non-3A4 substrates with a concomitant 
CYP3A4 inhibitor 
2. We found no overall difference in muscle toxicity, renal dysfunction, and hepatic dysfunction 
associated with statin 3A4 substrates compared to statin non-3A4 substrates with a concomitant 
CYP3A4 inhibitor 
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3. The stratified dose response analysis showed a non-significant increased hazard of muscle 
toxicity for high dose statin 3A4 substrates with a CYP3A4 inhibitor compared to high dose statin 
non-3A4 substrates with a CYP3A4 inhibitor 
4. The duration of response analysis showed a non-significant increased hazard of muscle 
toxicity in the first six months for statin 3A4 substrates with a CYP3A4 inhibitor compared to statin 
non-3A4 substrates with a CYP3A4 inhibitor 
5. In this large drug interaction study of statins and CYP3A4 inhibitors, the overall results show no 
evidence of increased hazard of statin-related adverse events based on statin metabolism  
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ABSTRACT 
Title: Statins and concomitant CYP3A4 inhibitors show no difference in statin-related adverse 
events based on statin metabolism 
Background: Although generally safe, statins have the potential for severe adverse reactions. 
Objective: To compare the relative hazard of muscle toxicity, renal dysfunction, and hepatic 
dysfunction between patients initiating statins metabolized by the CYP3A4 isoenzyme (statin-3A4 
substrates (atorvastatin & simvastatin)) to patients initiating statins not metabolized by the 
CYP3A4 isoenzyme (statin non-3A4 substrates (fluvastatin, pravastatin, and rosuvastatin)) with 
and without CYP3A4 inhibitor concomitancy.  
Methods: The Health Improvement Network (THIN) was used to conduct a retrospective cohort 
study from 1990-2008. Each cohort included new statin initiators and compared the relative 
hazard of statin-related adverse events. The interaction ratio (I*R) was the primary contrast of 
interest. The I*R represents the relative effect of each statin type (statin 3A4 substrate vs. statin 
non-3A4 substrate) with a CYP3A4 inhibitor, independent of the effect of the statin type without a 
CYP3A4 inhibitor. We adjusted for confounding variables using propensity scores. 
Results: The median follow-up time per cohort was 1.5 years. There were 7889 muscle toxicity 
events among 362,809 patients. The adjusted muscle toxicity I*R was 1.22 (95% CI: 0.90-1.66).  
There were 1449 renal dysfunction events among 272,099 patients. The adjusted renal 
dysfunction I*R was 0.91 (95% CI: 0.58-1.44).  There were 1434 hepatic dysfunction events 
among 367,612 patients. The adjusted hepatic dysfunction I*R was 0.78 (95% CI: 0.45-1.31).   
Conclusions: Overall, this study found no difference in the relative hazard of muscle toxicity, renal 
dysfunction, or hepatic dysfunction for patients prescribed a statin-3A4 substrate versus a statin 
non-3A4 substrate with CYP3A4 inhibitor concomitancy.  
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INTRODUCTION 
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are 
effective in the treatment of dyslipidemia, and have been shown to reduce the risk of major 
coronary outcomes and all cause mortality.1, 2 While statins are well tolerated by the vast majority 
of patients, they are associated with infrequent muscle, renal, and hepatic adverse events.3-9  
Statin associated muscle and renal toxicity occur on a continuum from minor myalgias and 
proteinuria to severe myositis, renal failure, and fatal rhabdomyolysis.10-12  Statin associated 
hepatic toxicity is characterized by transaminitis and rarely serious hepatic dysfunction or hepatic 
failure.13, 14  Clinical trials, case reports, and observational studies show these adverse events are 
associated with all marketed statins.9, 15-17 While the incidence of serious statin adverse events is 
low, muscle toxicity is a leading cause of statin discontinuation.18, 19  It has been shown that 
statin-related adverse events occur in a potency dependent manner and therefore may be 
exacerbated by pharmacokinetic (PK) statin-drug interactions that increase statin system 
exposure.8, 15, 20 17, 21 22-25   
Statin-drug interactions occur via inhibition of statin metabolic and/or non-metabolic (i.e., 
hepatic transport) pathways. Statin metabolism involves phase I oxidation (mediated by 
cytochrome P450 isoenzymes (CYP)) and phase II glucuronidation (mediated by UDP 
glucuronosyl transferase (UGT)). The specific hepatic isoenzymes mediating phase I statin 
metabolism are CYP3A4 (for atorvastatin and simvastatin), CYP2C8 (for cerivastatin), CPY2C9 
(for fluvastatin), and CYP2C19 (rosuvastatin). 41, 42  Pravastatin undergoes negligible metabolism 
by CYP isoenzymes.  It is primarily metabolized by glucuronidation (phase II). The non-metabolic 
statin pathways are mediated by influx and efflux transport proteins.  Inhibition of statin 
metabolism (phase I or II) and/or hepatic transport (influx or efflux) results in elevated statin 
plasma concentrations and prolonged systemic exposure, which has the potential to increase the 
risk for statin-related adverse events. 
Not all statins have the same drug interaction potential. The unique physiochemical property 
of each statin makes certain statins more likely to interact with concomitant medications. Of 
particular importance is the drug interaction between statins and drugs that inhibit the CYP3A4 
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metabolic pathway.  The CYP3A4 isoenzyme is the most prevalent isoenzyme in the cytochrome 
P450 enzyme system.  The CYP3A4 isoenzyme metabolizes more than 50% of marketed 
pharmaceuticals.26 Statins that undergo phase I metabolism by the CYP3A4 isoenzyme are 
referred to as statin 3A4 substrates (atorvastatin and simvastatin).  Statins that do no use the 
CYP3A4 isoenzyme metabolic pathway are referred to as statin non-3A4 substrates (pravastatin, 
fluvastatin, and rosuvastatin).  CYP3A4 inhibitors prevent CYP3A4 isoenzymes from metabolizing 
other drugs (e.g., statin 3A4 substrates). As serious statin adverse events are potency and 
plasma concentration related, it is recognized that plasma levels of statins 3A4 substrates may 
increase with concomitant administration of CYP3A4 inhibitors.27  Due to the documented 
increased systemic statin exposure (demonstrated through PK studies) and increased potential 
for adverse events, statin 3A4 substrate product labels warn against concomitant administration 
of these statins with CYP3A4 inhibitors.  Despite these warnings, statin 3A4 substrates and 
CYP3A4 inhibitors are frequently co-prescribed.51  Commonly used CYP3A4 inhibitors include 
calcium channel blockers, H2 receptor antagonists, antibiotics, antifungals, antidepressants, 
antiretrovirals, and immunosuppresants.28  
Studies quantifying the relative hazard of statin adverse events for different statins (with 
different metabolism) with CYP3A4 inhibitor concomitancy are limited.  The clinical importance of 
this drug interaction was described in an preliminary analysis of spontaneous adverse event 
reports associated with statin use.22  In this investigation, we compared the adverse event 
reporting rate (AER) and ratio (AERR) of rhabdomyolysis reports for simvastatin (a statin 3A4 
substrate) and pravastatin (a statin non-3A4 substrate) with versus without a CYP3A4 inhibitor.  
This study showed a six fold increase in the AERR for simvastatin (with vs. without a CYP3A4 
inhibitor) and no increase for pravastatin (with vs. without a CYP3A4 inhibitor).22  Given the 
limitations of spontaneous report analyses, further research was warranted to fully elucidate 
these findings. 
The purpose of the current investigation was to study the clinical importance of the drug 
interaction between statins and CYP3A4 inhibitors in a large retrospective cohort study.  Our 
specific aim was to determine the relative hazard of muscle toxicity, kidney dysfunction, and 
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hepatic dysfunction associated with statin 3A4 substrates compared to statin non-3A4 substrates 
with and without CYP3A4 inhibitor concomitancy.  Given the physiochemical properties, drug 
interaction potential, and prior research, we hypothesized an increased relative hazard for statin 
3A4 substrates compared to statin non-3A4 substrates with CYP3A4 inhibitor concomitancy.  
METHODS 
Study Population 
The study population was drawn from The Health Improvement Network (THIN) from 1990 
through October 2008.  THIN is an anonymized electronic medical record database of primary 
care medical records from the United Kingdom (UK). The database consists of contributions from 
415 general practices and data from more than three million actively registered patients (as of 
mid-year 2007).  Record selection was restricted to acceptable medical records, ensuring that 
only patients currently or once permanently registered with a general practice were included.68 
Statin initiators were eligible for cohort entry if they were eighteen years of age (at statin 
initiation) and registered with a general practice for twelve months prior to the first statin drug 
code. The twelve month period prior to statin initiation is referred to as the baseline period.  The 
rationale for requiring a twelve month baseline period prior to statin initiation is to collect baseline 
medical, therapy, outcome, and confounder data.   
Exclusion criteria were implemented based on information obtained prior to statin initiation. 
We excluded patients not continuously registered during the baseline period and those with a 
statin drug code prior to or during the baseline period. Cerivastatin initiators were excluded given 
the idiosyncratic increased risk for serious adverse events.  We excluded patients with an organ 
transplant. 
Definition of Exposure 
As noted, the cohort included subjects exposed to statins.  We categorized statin exposure 
by the metabolic properties of each statin with and without a concomitant CYP3A4 inhibitor. Statin 
3A4 substrates, metabolized by the CYP3A4 isoenzyme, included atorvastatin and simvastatin. 
Statin non-3A4 substrates, not metabolized by the CYP3A4 isoenzyme, included fluvastatin, 
pravastatin, and rosuvastatin. Statin potency was evaluated as a categorical, time varying 
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covariate. Statin potency categorization was based on percent low density lipoprotein cholesterol 
(LDL-C) reduction.69   
The four exposure categories included: statin 3A4 substrates with and without a concomitant 
CYP3A4 inhibitor and statin non-3A4 substrates with and without a concomitant CYP3A4 
inhibitor.  We identified CYP3A4 inhibitors from the University of Indiana's cytochrome P450 
table.28  We included concomitant exposure to the following CYP3A4 inhibitors: clarithromycin,52 
erythromycin,70 telithromycin, norfloxacin, diltiazem,25 verapamil,70 mibefradil71, amiodarone, 
ketoconazole,72 itraconazole,50 voriconazole, fluconazole72, nefazodone,73 fluvoxamine,74 
cyclosporine,47 cimetidine, ritonavir, saquinavir, nelfinavir, indinavir, lopinavir, imatinib, and 
aprepitant. For use in secondary analyses, a strong inhibitor was defined as one that causes 
greater than 5-fold increase in the plasma AUC values or more than 80% decrease in 
clearance.28 A moderate inhibitor was defined as one that causes a greater than 2-fold increase 
in the plasma AUC values or 50-80% decrease in clearance.28 
Follow-up was measured in person-time on a statin, either with or without a concomitant 
CYP3A4 inhibitor, beginning after the first day of the first statin drug code and continued with 
subsequent statin drug codes. Due to the pharmacology of the drug interaction, we excluded 
outcomes occurring on the first day of statin exposure.  Follow-up was censored at the first 
occurrence of: (i) the end of the statin days supplied (and no subsequent statin drug code), (ii) a 
drug code for a different statin (other than the one they initiated), (iii) the outcome in question, or 
(iv) the end of the study (October 2008). Each statin-exposed person-day was attributed to one of 
four exposure categories:  (i) a statin 3A4 substrate with a CYP3A4 inhibitor, (ii) a statin 3A4 
substrate without a CYP3A4 inhibitor, (iii) a statin non-3A4 substrate with a CYP3A4 inhibitor, and 
(iv) a statin non-3A4 substrate without a CYP3A4 inhibitor.   
Definition of Outcome 
To be classified as an outcome, the READ code or laboratory elevation must have occurred 
during or within thirty days following the end of included follow-up time, consistent with the work 
of Graham and colleagues.8 The thirty day period following the end of statin exposure (with no 
subsequent statin exposure) accounts for imperfect patient adherence and delayed outcome 
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recording. Outcomes were attributed to one of the four exposure categories. If an outcome 
occurred more than thirty days following included follow-up time, patient follow-up was censored.  
Outcome definitions were derived from recently published research on statin-related adverse 
events. 3-7, 75, 76 Each outcome was analyzed independently. We utilized medical diagnoses or 
laboratory evidence to identify incident outcomes.  Medical diagnoses are recorded in THIN using 
READ codes which are analogous to ICD-9 codes.  All READ codes and laboratory criteria were 
independently reviewed and verified by the study authors to identify muscle toxicity, renal 
dysfunction, and hepatic dysfunction (CR, SB, PR, JM, and JF).  
Muscle toxicity was defined by a READ code for muscle symptoms (e.g., myalgia, myopathy, 
myositis, and muscle pain) or a creatine kinase (CK) elevation greater than five times the upper 
limit of normal (>5 X ULN).   
Renal dysfunction was defined by a READ code for acute kidney injury, chronic kidney 
disease, end stage renal disease, dialysis, or a doubling of serum creatinine (sCr) (elevated to at 
least above the sCr upper limit of normal) over the baseline sCr or a single sCr value greater than 
twice the ULN (>2X ULN). The baseline sCr measurement was the lowest sCr value occurring 
within 365 days before the elevated sCr measurement.  A secondary analysis excluded patients 
with a READ code for chronic kidney disease. 
Hepatic dysfunction was defined as the first READ code for hepatic failure, toxic liver 
disease, acute liver necrosis, acute hepatitis, jaundice, or an ALT/AST measurement greater than 
five times the upper limit of normal (>5X ULN).  We utilized the 5X ULN ALT/AST outcome 
threshold, consistent with the Drug-Induced Liver Injury Network criteria.77 Additionally, we 
conducted a secondary analysis of severe transaminitis (using the ALT/AST threshold of 10X 
ULN). 
Outcomes identified by laboratory evidence were considered confirmed. Outcomes identified 
by READ codes with no laboratory evidence but with additional outcome evidence from physician 
comments in the electronic medical record were also considered confirmed. We conducted 
secondary analyses using confirmed outcomes only.  
Confounding Variables 
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We evaluated potential confounding variables associated with each outcome from previous 
research.17, 19, 21, 78  Patient demographics and medical history were collected during or prior to 
the twelve month baseline period prior to statin initiation.  Laboratory, patient surveillance, and 
pharmaceutical therapy data were collected only during the baseline period. Table 1 shows the 
specific potential confounding variables we evaluated.   
Due to incomplete baseline laboratory data (e.g., cholesterol, CK, sCr, and ALT/AST), only 
baseline cholesterol was evaluated as a potential confounder. The other laboratory measures 
were used to evaluate the patient surveillance rate.  That is, the number of normal (below the 
threshold for outcome/exclusion from the specific cohort) measurements during the baseline 
period.  
Analysis 
For each analysis, patients with documented evidence of the outcome prior to statin initiation 
were excluded, as were patients with chronic medical conditions related to that outcome.  For the 
analyses of muscle outcomes, we excluded those with prior codes for that outcome, and also 
those who ever had a code for dermatomyositis or myositis specifically attributed to another 
disorder. For the analyses of the renal dysfunction outcome, we excluded those with prior codes 
for that outcome, patients with a sCr above the upper limit of normal within the twelve months 
prior to statin initiation, and also those who ever had codes for genetic kidney disease and 
chronic nephritis.  For the analyses of the hepatic outcomes, we excluded patients with prior 
codes for that outcome, with an ALT or AST greater than 3X ULN within twelve months prior to 
statin initiation, and those who ever had a history of alcoholism and viral hepatitis. As noted, 
patients with chronic conditions (e.g., dermatomyositis, chronic nephritis, and alcoholism) were 
excluded, even if those chronic conditions were first diagnosed after cohort entry; since these 
were chronic conditions, we felt their appearance after cohort entry was simply a reflection of 
when the disease was recorded in the medical record, rather than the true onset of the condition. 
In a planned secondary analysis, we censored follow-up at documentation of these specific 
conditions, rather than excluding the entire patient record.  
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In descriptive analyses, continuous variables were described using means and categorical 
variables were described using percentages.  
The primary effect estimates were derived through Cox proportional hazards regression.79 
Statin potency was included as a time varying covariate in each analytic model. The contrast of 
interest is the interaction ratio (I*R). The I*R is a ratio of two hazard ratios (HR). It represents the 
relative hazard of each statin type with a concomitant CYP3A4 inhibitor adjusted for the hazard of 
each statin type without a CYP3A4 inhibitor.  This method controls for the hazard of the outcome 
associated with each statin type alone, thus, focusing on the effect on the differential hazard due 
to the statin-CYP3A4 inhibitor interaction.  
In addition to the primary analyses, we conducted secondary analyses of those with 
confirmed outcomes.  Other secondary analyses evaluated the effect of statin potency and 
duration of response.  
In order to evaluate different CYP3A4 inhibitor potencies, we conducted secondary analyses 
restricted to CYP3A4 inhibitors exhibiting moderate and strong inhibitory characteristics. We also 
conducted secondary analyses based on duration of CYP3A4 inhibitor use.  We evaluated the I*R 
for antibiotics and antifungals as short duration CYP3A4 inhibitors and other long duration use 
drugs (e.g., antihypertensives) as chronically used CYP3A4 inhibitors. We also present an 
analysis with specific concomitant CYP3A4 inhibitors. 
To control for confounding we used the multinomial propensity score. Multinomial propensity 
score methodology was described by Imai and Imbens and applied by Huang.61, 63, 64 The 
multinomial propensity score determines the probability of being in each exposure category given 
baseline covariates. Using the propensity score variable selection method described by 
Brookhart,80 we included only baseline variables associated (p<0.1) with the outcome.  This 
confounder selection procedure was conducted independently for each outcome. To assess 
baseline covariate balance we graphically evaluated the distribution of propensity scores for each 
of the four exposure categories. Graphic representation of propensity score distributions showed 
ample overlap to permit valid comparison among the four exposure categories (data not shown).   
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Missing data was handled using median value imputation and multiple imputation. For 
statins or CYP3A4 inhibitors missing the prescribed quantity or dosing instructions, we used 
median value imputation based on the derived median prescription duration for statins or 
CYP3A4 inhibitors with available prescribed quantity and dosing instructions. The proportion of 
statin and CYP3A4 inhibitor drug codes missing either the prescribed quantity or dosage 
instructions was 0.1 for statins and 0.2 for CYP3A4 inhibitors. Baseline body mass index (BMI) 
and cholesterol values were imputed using multiple imputation.81 We determined the average 
propensity score adjusted interaction ratio from ten imputed datasets.  Rubin's method was used 
to determine the variance; this method accounts for the within and between dataset variation.81, 82 
Monte Carlo simulation was used to estimate empiric power. Based on an estimated 
600,000 and 50,000 statin person-years with and without a concomitant CYP3A4 inhibitor 
(respectively), our empiric power simulations determined there was more than 80% power to 
detect an I*R of 2.0 (or above), for each outcome.  
Stata version 11.1 was used to perform all analyses. 
This study was approved by the Institutional Review Board at the University of Pennsylvania 
and registered with the National Health Service - Central Office for Research Ethics Committees 
(COREC), United Kingdom.  
RESULTS 
Figure 1 displays the subjects in the cohort who were excluded/included in each analysis. 
The median follow-up time in each analysis was 1.5 years (see Table 1).  Approximately 88% of 
patients initiated a statin 3A4 substrate.  Mean age, proportion of males, and BMI were balanced 
within between statin 3A4 substrate and statin non-3A4 substrate initiators.  
The results for muscle toxicity (primary and confirmed outcome analyses) are presented in 
Table 2a.  Baseline variables associated with muscle toxicity and therefore included in the 
propensity score adjusted model are listed at the bottom of Table 2a.  The adjusted relative 
hazard of muscle toxicity for each statin type with a concomitant CYP3A4 inhibitor, adjusted for 
the effect of each statin type without a CYP3A4 inhibitor is depicted by the I*R. The primary 
muscle toxicity adjusted I*R (95% CI) was 1.22 (0.90-1.66).  The confirmed muscle toxicity I*R 
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(adjusted) was 0.90 (0.53-1.52).  Muscle toxicity hazard ratios for each statin type with versus 
without a CYP3A4 inhibitor are presented in Table 2a.  
The results for renal dysfunction (primary analysis, confirmed outcome analysis, and CKD 
exclusion analyses) are presented in Table 2b.  The baseline variables included in the propensity 
score adjusted model are listed at the bottom of Table 2b. For the primary renal dysfunction 
analysis the adjusted I*R was 0.91 (0.57-1.43).  The confirmed renal dysfunction outcome I*R 
(adjusted) was 0.86 (0.50-1.45).  The adjusted I*R excluding CKD outcomes was 0.91 (0.55-
1.49).  Renal dysfunction hazard ratios for each statin type with versus without a CYP3A4 
inhibitor are presented in Table 2b. 
The results for hepatic dysfunction (primary, confirmed, and ALT/AST >10X ULN) are 
presented in Table 2c.  The baseline variables included in the propensity score adjusted model 
are listed at the bottom of Table 2c. For the primary analysis the adjusted I*R for renal 
dysfunction was 0.78 (0.45-1.33).  The confirmed hepatic dysfunction outcome (adjusted) I*R was 
0.66 (0.38-1.14).  The adjusted I*R for the ALT/AST 10X ULN was 0.85 (0.39-1.87).  Hepatic 
dysfunction hazard ratios for each statin type with versus without a CYP3A4 inhibitor are 
presented in Table 2c. 
Statin potency analyses are presented in Table 3.  The table shows specific statin dosages 
included in each category.  The test for trend among the muscle toxicity potency strata was not 
significant (p=0.46). For renal dysfunction, due to sparse events (and person-years) in the statin 
non-3A4 substrate with a CYP3A4 inhibitor exposure category, we could not obtain an interaction 
ratio in the high potency strata.  
Duration of response analyses are presented in Table 4.  Due to sparse events in the statin 
non-3A4 substrate with a CYP3A4 inhibitor exposure category, we could not obtain stable 
interaction ratios earlier than six months following statin initiation.  We also attempted to 
determine the I*R during the first course of statin therapy, but there were insufficient person-years 
and events to obtain stable I*R estimates.  Given this, we stratified the duration of follow-up as 
follows: 0-6 months, 6-12 months, 12-24 months, and >24 months.   
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Table 5 describes the person-years and events for specific CYP3A4 inhibitors jointly 
prescribed with statins.  Overall, the concomitant statin-CYP3A4 inhibitor person-years and 
events were similarly distributed for patients exposed to statin 3A4 substrates and statin non-3A4 
substrates.  For each cohort, diltiazem, verapamil, and amiodarone make up nearly 85% of all 
CYP3A4 inhibitor concomitancy among statin users.   
The results from the secondary analysis censoring follow-up for patients with specific chronic 
medical conditions identified after statin initiation rather than excluding the entire patient record 
were consistent with the primary findings (data not shown). For each outcome, the I*R from the 
moderate/strong CYP3A4 inhibitor analysis and the short/chronic CYP3A4 inhibitor analysis were 
consistent from the primary analysis findings (data not shown).  
DISCUSSION 
For each outcome, the primary and confirmed analyses show no significant increased 
hazard associated with statin 3A4 substrates compared to statin non-3A4 substrates with a 
concomitant CYP3A4 inhibitor, adjusted for the hazard of each statin type without a concomitant 
CYP3A4 inhibitor. The I*R is an appropriate effect estimate for evaluating the clinical importance 
of drug interactions provided a suitable comparator group is available. For the primary and 
confirmed outcome analyses, statin person-years in each of the four exposure categories 
contributed sufficient person-years to allow I*R estimation. The results from this investigation 
indicate the clinical implications of this well documented drug interaction may be of less 
importance than suggested by pharmacokinetic studies, case reports, and analyses of 
spontaneous reports. 
Pharmacokinetic studies consistently show rapidly increased systemic statin exposure with 
co-administration of statin 3A4 substrates and a CYP3A4 inhibitor compared to statin 3A4 
substrates alone.71, 83-85  The results of this study suggest the short term increased systemic statin 
exposure does not translate into increased hazard for statin-related adverse events. We 
evaluated the early effect this drug interaction by conducting a duration-of-response analysis. For 
renal and hepatic dysfunction, the I*R showed no increased hazard in the first six months 
following statin initiation.  For muscle toxicity, the I*R showed a non-significant increased hazard 
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in the first six months following statin initiation (I*R=2.07 (0.95-4.48)). Further evaluation of 
muscle toxicity may be warranted within six months following the joint exposure to statins and 
CYP3A4 inhibitors. 
Previous research shows statin potency is associated with muscle toxicity.19, 21  As expected, 
we saw an increase in the hazard of all three outcomes for each successive increase in statin 
potency, not quite statistically significant for renal dysfunction (data not shown). However, the 
continuous potency analysis shows the association between statin potency and the outcome, but 
does not address the differential hazard for each statin type with a CYP3A4 inhibitor, compared to 
each statin type without a CYP3A4 inhibitor. This contrast (i.e., the I*R) is depicted in the stratified 
potency analyses, where the interaction ratios show no increasing effect in subsequent potency 
strata.  
Other recent observational studies evaluated statin-associated adverse events with 
concomitant CYP3A4 inhibitors. Cziraky and colleagues reported a six fold (RR=6.01 95% CI 
(2.08-17.38)) increased risk of muscle toxicity for statins with CYP3A4 inhibitors compared to 
atorvastatin alone.9 However, statin exposure was aggregated among all person-years attributed 
to cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin with a 
concomitant CYP3A4 inhibitor. Stratification of statin exposure by oxidative metabolism was not 
evaluated, so they could not disaggregate the independent risk from the CYP3A4 inhibitor from 
the risk from the drug interaction. In the present study, the interaction ratio separates the effect of 
the statin type with a CYP3A4 inhibitor from the effect of each statin type without a CYP3A4 
inhibitor.   
The results from the present study are also discordant from our preliminary spontaneous 
report study in which we found a six fold increased adverse event reporting rate ratio (AERR) for 
simvastatin reports with a concomitant CYP3A4 inhibitor compared to simvastatin reports without 
a concomitant CYP3A4 inhibitor.22  Substantial methodologic differences favoring validity in the 
present study likely drive the inconsistent finding.  The present study included only new statin 
initiators, excluded patients with prior outcomes, excluded organ transplant patients, used a 
validated electronic medical record database, adjusted for potential confounding variables, had a 
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true denominator of statin person-years with and without CYP3A4 inhibitor concomitancy, was not 
dependent on external outcome reporting, and used Cox proportional hazards regression to 
estimate the interaction ratio with 95% confidence intervals. Spontaneous report analyses are 
critical for signal generation. However, the conclusiveness of their findings is limited.86 The 
present study is the largest observational study specifically designed to evaluate the clinical 
importance of the statin-CYP3A4 inhibitor drug interaction.  
THIN has been used in many epidemiologic studies and has been validated for numerous 
medical conditions including studies of statin-related side effects.87-89 Despite this, practice 
patterns, patient populations, prescribing patterns, and patient surveillance may be systematically 
different in the UK from in other countries.  We compared the baseline patient characteristics in 
this study to those in other recent statin safety investigations.3-7, 9, 75, 78, 90, 91 These baseline 
patient characteristics were consistent with the baseline patient characteristics from other US, 
Canadian, and European statin safety cohorts.   
Regarding confounding, we did not control for variables which we could not identify or could 
not measure.  However, we captured important variables previously shown to be risk factors for 
each outcome.   We also separately controlled for confounding by chronic diseases, whether they 
were diagnosed before or after the initiation of the statin; the results were the same. 
We addressed potential bias associated with depletion of susceptibles by including only new 
statin initiators.  The rationale for employing the new user design is to circumvent under-
ascertainment of outcomes occurring early in therapy and to evaluate potential confounders prior 
to statin exposure.  This is important because some potential confounders (e.g., cholesterol) may 
change as a result of statin exposure.  Furthermore, if outcomes occurred rapidly following statin 
initiation, as was expected with muscle toxicity and hepatic dysfunction, and if the occurrence of 
these early outcomes were associated with statin type, our estimates would be biased.  The new 
user design diminishes this risk of this potential bias. 
In order to minimize exposure misclassification, we defined precise exposure criteria for 
each exposure category, used up to date drug codes, and carefully constructed exposure 
episodes. Use of THIN diminishes the possibility of poor medication adherence, since in the UK 
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patients are given only a 28-day prescription at a time.  Regardless, we would not expect 
medication adherence to differ by statin type.  
One noteworthy class of CYP3A4 inhibitors not represented in this investigation is 
antiretroviral therapy (e.g., ritonavir, saquinavir, nelfinavir, indinavir, and lopinavir).  This 
investigation included person-years of concomitant exposure to statins and antiretrovirals, but 
there was negligible use included in THIN.  In the UK, antiretroviral treatment is given mainly by 
specialized genitourinary medical clinics, not by physicians in general practice.  The results from 
this investigation may or may not extrapolate to statins with concomitant antiretroviral therapy.  
Outcome misclassification threatens the validity of all retrospective cohort studies. To 
evaluate potential outcome misclassification, we conducted secondary analyses restricted to 
confirmed outcomes. This provided a sensitivity analysis to reveal the accuracy of our original 
outcome classification; the findings from the confirmed outcome analyses were consistent with 
the primary analyses.   
Conclusion 
This large retrospective cohort study showed no overall increased hazard for muscle toxicity, 
renal dysfunction, or hepatic dysfunction associated with statin 3A4 substrates compared to statin 
non-3A4 substrates with versus without a concomitant CYP3A4 inhibitor. Additional research 
could further evaluate the non-significant yet increased muscle toxicity interaction ratio we 
observed for highly potent statin dosages and within six months following statin initiation. 
However, it is clear that the drug interaction between statins and CYP3A4 inhibitors does not 
represent an important public health concern. 
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TABLES 
THIN FIGURE 1 
Total statin users
 (1990-2008) Prevalent/former statin users
n=487,727 n=106,539 Cerivastatin initiators
Organ transplant patients
n=18,379 Muscle cohort
n=109,089 Renal cohort
n=13,576 Hepatic cohort
Subjects included in 
the muscle cohort
Subjects included in 
the renal cohort
n=362,809 n=272, 099 n=367,612
Excluded from all cohorts:
n=381,188
Figure 1. Subjects excluded/included in the muscle, renal, hepatic cohorts
Subjects included in 
the hepatic cohort
Excluded because of outcome evidence prior 
to the first statin or other chronic muscle, 
renal, or hepatic disorders
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THIN TABLE 1 
Baseline characteristics Statin 3A4 
substrate
Statin non-
3A4 substrate
Statin 3A4 
substrate
Statin non-
3A4 substrate
Statin 3A4 
substrate
Statin non-
3A4 substrate
# of statin initiators 325,460 37,349 243,707 28,392 329,668 37,944
Age (mean) 63 64 62 62 64 63
<54 22% 22% 26% 27% 21% 22%
55-64 29% 30% 32% 32% 29% 30%
65-74 30% 32% 28% 29% 30% 32%
>75 20% 17% 14% 13% 20% 17%
Male 54% 54% 56% 56% 53% 53%
BMI (mean) 28 28 28 28 28 28
Alcoholism 1.6% 1.3% 1.9% 1.5% excluded excluded
Current smoker 11% 6% 12% 6% 11% 6%
Medical diagnoses (anytime prior to statin initiation)
CHF 4% 5% 2% 3% 4% 5%
Previous MI 28% 37% 26% 35% 28% 37%
Previous Stroke 4% 5% 4% 4% 4% 5%
Diabetes 21% 19% 19% 16% 21% 19%
Hypertension 52% 49% 47% 45% 52% 49%
Hypothyroidism 4% 4% 4% 3% 5% 4%
Acute kidney disease 0.5% 0.4% excluded excluded 0.5% 0.4%
Chronic kidney disease 3.4% 1.2% excluded excluded 3.4% 1.2%
Acute liver disease 0.4% 0.3% 0.3% 0.3% excluded excluded
Chronic liver disease 0.3% 0.2% 0.3% 0.3% excluded excluded
Subject Surveillance Rate  (within 12 months prior to statin initiation)
Office visits 2.0 1.7 1.8 1.6 2.0 1.7
Serum creatinine 1.0 0.6 0.9 0.6 1.0 0.6
ALT or AST 0.7 0.4 0.7 0.4 0.7 0.4
Baseline labs  (within12 months prior to statin initiation)
Total cholesterol (mmol/L)
n 273,245 26,734 202,169 19,707 276,993 27,150
% w/measurement 84.0 71.6 83.0 69.4 84.0 71.6
mean cholesterol 6.3 6.4 6.3 6.5 6.3 6.4
Serum creatinine (sCr) (μmol/L)
n 235,183 18,122 166,387 12,124 238,169 18,395
% w/measurement 72.3 48.5 68.3 42.7 72.2 48.5
mean sCr 93.1 95.1 83.9 84.9 93.1 95.1
ALT or AST (U/L)
n 150,614 8,827 109,144 6,195 151,670 8,887
% w/measurement 46.3 23.6 44.8 21.8 46.0 23.4
mean ALT 28.8 29.1 30.1 30.1 27.3 27.3
Creatine Kinase (CK) (U/L)
n 16,090 1,120 11,625 800 17,012 1,172
% w/measurement 4.9 3.0 4.8 2.8 5.2 3.1
mean CK 112.1 112.0 126.0 131.2 122.8 124.3
First statin
Atorvastatin 26% - 25% - 26% -
Simvastatin 74% - 75% - 74% -
Fluvastatin - 17% - 17% - 17%
Pravastatin - 64% - 63% - 64%
Rosuvastatin - 19% - 20% - 19%
Standardized statin potency category (at statin initiation)
Low 20% 59% 20% 59% 20% 59%
Medium 49% 23% 49% 22% 49% 23%
High 31% 18% 31% 19% 31% 18%
Pharmacotherapy (at statin initiation)
CYP3A4 inhibitor 6% 8% 5% 7% 6% 8%
Diabetes drug 11% 10% 10% 8% 11% 10%
Hypertension drug 63% 64% 57% 60% 63% 65%
Thyroid drug 7% 7% 6% 6% 7% 7%
Gemfibrozil 0.1% 0.1% 0.1% 0.2% 0.1% 0.1%
Other fibrate 1.1% 1.8% 1.0% 1.8% 1% 2%
Niacin 0.0% 0.0% 0.0% 0.0% 0.01% 0.01%
Vitamin D 2.0% 1.4% 1.6% 1.1% 0% 0%
Hepatic cohortMuscle cohort Renal cohort
Table 1. Subject characteristics - (at or prior to the first statin)
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THIN TABLE 2A 
Unadjusted Adjusted† Unadjusted Adjusted†
Primary analysis
0.93 0.97
(0.85-1.03) (0.88-1.07)
1.20 1.22
(0.89-1.63) (0.90-1.66)
0.76 0.75
(0.57-1.01) (0.56-1.00)
Totals 7889 792665 9.95
Confirmed outcomes
0.79 0.88
(0.66-0.94) (0.74-1.06)
0.87 0.90
(0.52-1.48) (0.53-1.52)
0.89 0.94
(0.54-1.46) (0.57-1.55)
Totals 2718 792665 3.43
Events
2.35
statin 3A4 substrate 2358
50608 8.81
statin 3A4 substrate*
statin non-3A4 substrate +  CYP3A4X 49
HR (95% CI) I*R (95% CI) 
IRp-y
†Model adjusted for the following baseline variables (i.e., at or prior to statin initiation): age, sex, cholesterol, year at statin initiation, CHF, 
stroke, diabetes, hypothyroidism, fluoroquinolone antibiotics, diabetes drugs, thyroid drugs, number of office visits, sCr measurements, 
and ALT/AST measurements during the baseline period, statin potency (as a time varying covariate)
3.59
9.10
2.73
statin non-3A4 substrate +  CYP3A4X
657276
Table 2a. Muscle toxicity analyses: number of events (events), person-years (p-y), incidence rates per 1000 person 
years (IR), unadjusted and adjusted hazard ratios (HR), and unadjusted and adjusted interaction ratios (I*R)
statin 3A4 substrate + CYP3A4X 131 50608 2.59
statin 3A4 substrate‡ + CYP3A4X↑ 446
6688 657276 10.18
7227 6.78
statin non-3A4 substrate 212 77555
statin non-3A4 substrate 706 77555
17 7227
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THIN TABLE 2B 
Unadjusted Adjusted† Unadjusted Adjusted†
Primary
2.10 1.69
(1.79-2.46) (1.43-1.99)
0.95 0.91
(0.60-1.50) (0.57-1.43)
2.21 1.80
(1.44-3.39) (1.16-2.79)
Totals 1449 574584 2.52
Confirmed outcomes
2.53 2.15
(2.09-3.05) (1.77-2.60)
0.90 0.86
(0.51-1.46) (0.50-1.45)
2.80 2.23
(1.71-4.56) (1.35-3.69)
Totals 934 574584 1.63
2.20 1.75
(1.85-2.62) (1.46-2.08)
0.96 0.91
(0.59-1.57) (0.55-1.49)
2.27 1.79
(1.44-3.60) (1.12-2.86)
Totals 1220 574601 2.12
HR (95% CI) I*R (95% CI) 
Events p-y IR
statin 3A4 substrate + CYP3A4X 152 33543 4.53
statin 3A4 substrate 935 478847 1.95
statin non-3A4 substrate 82 57339 1.43
statin non-3A4 substrate +  CYP3A4X 20 4872 4.10
statin 3A4 substrate 701 478830 1.46
Table 2b. Renal dysfunction analyses: number of events (events), person-years (p-y), incidence rates per 1000 
person years (IR), unadjusted and adjusted hazard ratios (HR), and unadjusted and adjusted interaction ratios (I*R)
statin 3A4 substrate + CYP3A4X 131 33543 3.91
statin non-3A4 substrate 130 57339 2.27
statin non-3A4 substrate +  CYP3A4X 25 4872 5.13
statin 3A4 substrate 1119 478830 2.34
statin 3A4 substrate + CYP3A4X 175 33543 5.22
Excluding chronic kidney disease outcomes
†Model adjusted for the following baseline variables (i.e., at or prior to statin initiation): age, sex, BMI, cholesterol, alcoholism, year at statin 
initiation, CHF, MI, stroke, diabetes, hypertension, vitamin D, diabetes drug use, hypertension drug use, # of office visits during the baseline 
period, statin potency (as a time varying covariate)
statin non-3A4 substrate 111 57339 1.94
statin non-3A4 substrate +  CYP3A4X 22 4872 4.52
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THIN TABLE 2C 
Unadjusted Adjusted† Unadjusted Adjusted†
Primary analysis
1.25 1.19
(1.03-1.52) (0.97-1.44)
0.78 0.78
(0.46-1.32) (0.46-1.33)
1.62 1.64
(0.99-2.66) (0.98-2.72)
Totals 1434 815945 1.76
Confirmed outcomes
1.21 1.20
(0.98-1.50) (0.97-1.49)
0.65 0.66
(0.37-1.11) (0.38-1.14)
1.86 2.01
(1.12-3.07) (1.20-3.36)
Totals 1241 815945 1.52
ALT/AST 10X ULN OR med codes
1.27 1.14
(0.97-1.65) (0.87-1.49)
0.86 0.85
(0.39-1.88) (0.39-1.87)
1.47 1.34
(0.70-3.09) (0.63-2.86)
Totals 754 816000 0.92
HR (95% CI) I*R (95% CI) 
Events p-y IR
statin non-3A4 substrate 102 80052 1.27
statin non-3A4 substrate +  CYP3A4X 18 7624 2.36
statin 3A4 substrate 1024 675312 1.52
Table 2c. Hepatic dysfunction analyses: number of events (events), person-years (p-y), incidence rates per 1000 person 
years (IR), unadjusted and adjusted hazard ratios (HR), and unadjusted and adjusted interaction ratios (I*R)
statin 3A4 substrate + CYP3A4X 97 52957 1.83
statin non-3A4 substrate 117 80052 1.46
statin non-3A4 substrate +  CYP3A4X 18 7624 2.36
statin 3A4 substrate 1183 675312 1.75
statin 3A4 substrate + CYP3A4X 116 52957 2.19
statin 3A4 substrate + CYP3A4X 62 52961 1.17
statin 3A4 substrate 627 675358 0.93
statin non-3A4 substrate +  CYP3A4X 8 7625 1.05
†Model adjusted for the following baseline variables (i.e., at or prior to statin initiation): age, sex, cholesterol, year at statin initiation, CHF, MI, 
stroke, diabetes, hypertension, hypothyroidism, diabetes drugs, hypertension drugs, # of office visits, sCr measurements, ALT/AST 
measurements in the 12 months prior to statin initiation, statin potency (as a time varying covariate)
statin non-3A4 substrate 57 80056 0.71
 
 
 
73
 
THIN TABLE 3 
Outcome
Statin 
Potency†
# of 
Events
Person-
years
IR/1000 p-y
Adjusted‡ 
I*R
95% CI
low1 1436 166470 8.63 1.06 (0.87-1.12)
medium2 3405 348824 9.76 1.28 (0.77-2.11)
high3 3048 277371 10.99 2.85 (0.70-11.62)
low 291 120934 2.41 0.84 (0.39-1.83)
medium 620 251108 2.47 0.78 (0.42-1.45)
high 538 202542 2.66 - -
low 257 171580 1.50 0.51 (0.22-1.15)
medium 609 359195 1.70 1.27 (0.97- 1.67)
high 568 284086 2.00 0.97 (0.13-7.45)
‡ Models adjusted for the same variables in the primary analysis.  See tables 3a, 3b, 3c for specific variables.
Table 3. Standardized potency† analysis
Muscle toxicity
Renal dysfunction
Hepatic dysfunction
1 Low potency: < 25% LDL-C reduction (atorvastatin <=5mg, simvastatin <=10mg, fluvastatin <=20mg, pravastatin 
<=20)
2 Medium potency: 25-30% LDL-C reduction (atorvastatin 10mg, simvastatin 20mg, fluvastatin 80mg, pravastatin 40)
3 High potency: is >30% LDL-C reduction  (atorvastatin >=20mg, simvastatin >=40mg, fluvastatin 160mg, pravastatin 
>=80, rosuvastatin >=5mg)
† Statin potency standardization
 
 
 
74
THIN TABLE 4 
cyp + cyp - cyp + cyp -
0-6 events 122 2520 7 211 2860
p-years 6509 104377 1019 11781 123685
6-12 events 63 1082 10 89 1244
p-years 6678 106370 1018 11772 125838
12-24 events 78 1264 8 137 1487
p-years 10988 160601 1629 18213 191431
>24 events 183 1822 24 269 2298
p-years 26433 285624 3561 35789 351408
0-6 events 22 198 3 19 242
p-years 4363 78150 710 8959 92183
6-12 events 17 153 3 12 185
p-years 4454 78550 699 8821 92524
12-24 events 30 210 5 25 270
p-years 7236 117080 1097 13524 138937
>24 events 106 558 14 74 752
p-years 17489 205049 2366 26035 250939
0-6 events 17 296 4 23 340
p-years 6702 105868 1061 11982 125614
6-12 events 11 172 2 15 200
p-years 6904 108304 1063 12035 128305
12-24 events 21 259 4 25 309
p-years 11387 164342 1704 18696 196130
>24 events 67 456 8 54 585
p-years 27964 296798 3796 37339 365897
Table 4. Duration of response analysis for muscle toxicity, renal dysfunction, and hepatic dysfunction stratified 
by statin 3A4 substrates and statin non-3A4 substrates with and without a CYP3A4 inhibitor (cyp). 
Muscle 
toxicity
IR/1000 
p-y
Events & P-
years
Months
9.89 0.72
7.77 1.37
Statin 3A4 substrate
3.00 0.99
Adjusted‡ 
I*R
Statin non-3A4 
substrate
23.12 2.07
(0.54-1.82)
6.54 1.20
1.94 0.89 (0.32-2.51)
(0.26-3.51)
2.00 0.60 (0.15-2.33)
(0.95-4.49)
(0.36-1.44)
(0.65-2.89)
(0.79-1.87)
0.65 (0.13-3.19)
Renal 
dysfunction
Hepatic 
dysfunction
2.71 0.43
1.58 0.67
2.63 0.96
Outcome Totals 95% CI
‡ Models adjusted for the same variables in the primary analysis.  See tables 3a, 3b, 3c for specific variables.
(0.21-2.09)
1.60 1.08 (0.49-2.36)
(0.13-1.38)
1.56
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THIN TABLE 5 
p-years %† Events p-years %† Events p-years %† Events p-years %† Events p-years %† Events p-years %† Events
Statin w/o CYP3A4 inhibitor 657726 - 6688 77555 - 706 478830 - 1119 57339 - 130 675312 - 1183 80052 - 117
Statin w/ CYP3A4 inhibitor 50608 - 446 7227 - 49 33543 - 175 4872 - 25 52957 - 116 7624 - 18
Diltiazem 36770 72.75 330 5083 70.65 36 25835 77.04 85 3644 74.88 9 38558 73.05 57 5318 70.89 11
Amiodarone 7644 15.11 57 1214 16.78 7 3548 10.58 67 623 12.81 11 7807 14.79 42 1243 16.57 7
Cimetidine 3218 6.37 22 483 6.71 1 2048 6.11 10 309 6.35 1 3361 6.37 9 500 6.66 1
Verapamil 2111 4.18 29 283 3.93 2 1481 4.42 7 198 4.08 1 2211 4.19 4 288 3.84 -
Erythromycin 777 1.54 9 98 1.36 - 545 1.63 2 72 1.48 - 816 1.55 2 104 1.39 -
Clarithromycin 447 0.88 4 70 0.98 - 321 0.96 6 51 1.06 2 474 0.90 1 74 0.99 -
Cyclosporine 183 0.36 2 66 0.92 3 63 0.19 2 29 0.59 1 179 0.34 1 65 0.87 -
Fluconazole 101 0.20 1 13 0.18 - 76 0.23 1 8 0.17 - 106 0.20 1 13 0.18 -
Fluvoxamine 80 0.16 1 9 0.13 - 68 0.20 - 8 0.17 - 75 0.14 - 9 0.13 -
Nefazadone 42 0.08 - 16 0.22 - 33 0.10 - 13 0.26 - 48 0.09 - 15 0.19 -
Itraconazole 34 0.07 - 5 0.07 - 27 0.08 - 3 0.06 - 34 0.07 - 5 0.07 -
Norfloxacin 23 0.05 - 3 0.04 - 18 0.05 - 2 0.04 - 27 0.05 - 3 0.04 -
Ketoconazole 3 0.01 - 1 0.01 - 3 0.01 - 0 0.00 - 3 0.01 - 1 0.01 -
Mibefradil 2 0.00 - 4 0.05 - 1 0.00 - 3 0.06 - 2 0.00 - 4 0.05 -
Imatinib 0 0.00 - - - - 0 0.00 - - - - 0 0.00 - - - -
Voriconazole 0 0.00 - 0 0.00 - 0 0.00 - - - - 0 0.00 - 0 0.00 -
† percent of total concomitant statin plus CYP3A4 inhibitor person-years
Muscle toxicity Renal dysfunction
Statin 3A4 substrate
Statin non-3A4 
substrate
Statin 3A4 substrate
Statin non-3A4 
substrate
Statin 3A4 substrate Statin non-3A4 substrate
Hepatic dysfunction
Table 5. Descriptive analysis of statin person-years and events with and without specific concomitant CYP3A4 inhibitors for muscle toxicity, renal dysfunction, 
and hepatic dysfunction stratified by statin 3A4 substrates and statin non-3A4 substrates.
Specific concomitant CYP3A4 inhibitors
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DISSERTATION CONCLUSION 
 
This research endeavor evaluated the clinical importance of the drug interaction between 
statins and CYP3A4 inhibitors.  Two empiric investigations and a methodologic study were 
conducted.  The preliminary empiric study (the AERS study) showed an increased adverse event 
reporting rate of rhabdomyolysis for simvastatin, a statin 3A4 substrate statin, with a concomitant 
CYP3A4 inhibitor. There was no increased adverse event reporting rate for pravastatin, a statin 
non-3A4 substrate, with a concomitant CYP3A4 inhibitor.  These results supported observations 
in clinical trials and case reports regarding increased risk of muscle toxicity for statin 3A4 
substrates with concomitant CYP3A4 inhibitors. However, substantial limitations of internal 
validity, inherent in spontaneous report analyses, warranted additional research to fully elucidate 
these findings. 
To assess the validity of the multinomial propensity score, we evaluated the statistical 
performance of different propensity score methods in the setting of a simulated drug interaction 
study. The results from this methodologic investigation showed the multinomial propensity score 
reduced bias, had greater coverage probability, and increased precision than comparator binary 
propensity score methods. Investigators studying drug-drug interactions may consider the 
multinomial propensity score approach for confounding adjustment. 
To further address the clinical importance of this drug interaction, we conducted a 
retrospective cohort study in the THIN database (the THIN study).   This was the largest study 
specifically designed to evaluate statin-related adverse events based on statin metabolism with 
CYP3A4 inhibitor concomitancy.  We used a multinomial propensity score to control confounding. 
The results of this study showed no overall increased hazard for muscle toxicity, renal 
dysfunction, or hepatic dysfunction associated with statin 3A4 substrates compared to statin non-
3A4 substrates with versus without a concomitant CYP3A4 inhibitor. We only identified a non-
significant increased hazard of muscle toxicity for highly potent statin dosages and within six 
months following statin initiation for statin 3A4 substrates compared to statin non-3A4 substrates.   
Given the magnitude of this investigation, the drug interaction between statins and CYP3A4 
inhibitors does not represent a substantial public health concern.   
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